==DOCSTART==	
DCTN4	O
as	O
a	O
modifier	O
of	O
chronic	B-Disease
Pseudomonas	I-Disease
aeruginosa	I-Disease
infection	I-Disease
in	O
cystic	B-Disease
fibrosis	I-Disease
Pseudomonas	B-Disease
aeruginosa	I-Disease
(Pa)	I-Disease
infection	I-Disease
in	O
cystic	B-Disease
fibrosis	I-Disease
(	O
CF	B-Disease
)	O
patients	O
is	O
associated	O
with	O
worse	O
long-term	O
pulmonary	B-Disease
disease	I-Disease
and	O
shorter	O
survival	O
,	O
and	O
chronic	B-Disease
Pa	I-Disease
infection	I-Disease
(	O
CPA	B-Disease
)	O
is	O
associated	O
with	O
reduced	B-Finding
lung	I-Finding
function	I-Finding
,	O
faster	B-Finding
rate	I-Finding
of	I-Finding
lung	I-Finding
decline	I-Finding
,	O
increased	O
rates	O
of	O
exacerbations	B-Finding
and	O
shorter	O
survival	O
.	O
By	O
using	O
exome	B-Molecular
sequencing	I-Molecular
and	O
extreme	O
phenotype	O
design	O
,	O
it	O
was	O
recently	O
shown	O
that	O
isoforms	B-Amino
of	O
dynactin	O
4	O
(DCTN4)	O
may	O
influence	O
Pa	B-Disease
infection	I-Disease
in	O
CF	B-Disease
,	O
leading	O
to	O
worse	O
respiratory	B-Disease
disease	I-Disease
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
DCTN4	O
missense	B-Finding
variants	B-Amino
on	O
Pa	B-Disease
infection	I-Disease
incidence	O
,	O
age	O
at	O
first	O
Pa	B-Disease
infection	I-Disease
and	O
chronic	B-Disease
Pa	I-Disease
infection	I-Disease
incidence	O
in	O
a	O
cohort	O
of	O
adult	O
CF	B-Disease
patients	O
from	O
a	O
single	O
centre.	O
Polymerase	B-Molecular
chain	I-Molecular
reaction	I-Molecular
and	O
direct	B-Molecular
sequencing	I-Molecular
were	O
used	O
to	O
screen	O
DNA	B-Cell
samples	I-Cell
for	O
DCTN4	O
variants	B-Amino
.	O
A	O
total	O
of	O
121	O
adult	O
CF	B-Disease
patients	O
from	O
the	O
Cochin	O
Hospital	O
CF	O
centre	O
have	O
been	O
included,	O
all	O
of	O
them	O
carrying	O
two	O
CFTR	O
defects	O
:	O
103	O
developed	O
at	O
least	O
1	O
pulmonary	B-Disease
infection	I-Disease
with	O
Pa	B-Bacterium
,	O
and	O
68	O
patients	O
of	O
them	O
had	O
CPA	B-Disease
.	O
DCTN4	O
variants	B-Amino
were	O
identified	O
in	O
24%	O
(29/121)	O
CF	B-Disease
patients	O
with	O
Pa	B-Disease
infection	I-Disease
and	O
in	O
only	O
17%	O
(3/18)	O
CF	B-Disease
patients	O
with	O
no	O
Pa	B-Disease
infection	I-Disease
.	O
Of	O
the	O
patients	O
with	O
CPA	B-Disease
,	O
29%	O
(20/68)	O
had	O
DCTN4	O
missense	B-Finding
variants	B-Amino
vs	O
23%	O
(8/35)	O
in	O
patients	O
without	O
CPA	B-Disease
.	O
Interestingly,	O
p.Tyr263Cys	B-Amino
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
CF	B-Disease
patients	O
with	O
CPA	B-Disease
than	O

==DOCSTART==	
in	O
patients	O
without	O
CPA	B-Disease
(4/68	O
vs	O
0/35),	O
and	O
DCTN4	O
missense	B-Finding
variants	B-Amino
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
CF	B-Disease
patients	O
with	O
CPA	B-Disease
bearing	O
two	O
class	B-Genetic
II	I-Genetic
mutations	I-Genetic
than	O
in	O
male	O
CF	B-Disease
patients	O
without	O
CPA	B-Disease
bearing	O
two	O
class	B-Genetic
II	I-Genetic
mutations	I-Genetic
(P	O
=	O
0.06).	O
Our	O
observations	O
reinforce	O
that	O
DCTN4	O
missense	B-Finding
variants	B-Amino
,	O
especially	O
p.Tyr263Cys	B-Amino
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	B-Pathologic
of	O
CPA	B-Disease
in	O
male	O
CF	B-Disease
.	O

==DOCSTART==	
Nonylphenol	B-Hazardous
diethoxylate	I-Hazardous
inhibits	O
apoptosis	B-Cell
induced	O
in	O
PC12	B-Cell
cells	I-Cell
Nonylphenol	B-Hazardous
and	O
short-chain	B-Hazardous
nonylphenol	I-Hazardous
ethoxylates	I-Hazardous
such	O
as	O
NP2	B-Hazardous
EO	I-Hazardous
are	O
present	B-Finding
in	O
aquatic	O
environment	O
as	O
wastewater	O
contaminants	O
,	O
and	O
their	O
toxic	B-Injury
effects	I-Injury
on	O
aquatic	O
species	O
have	O
been	O
reported.	O
Apoptosis	B-Cell
has	O
been	O
shown	O
to	O
be	O
induced	O
by	O
serum	B-Body
deprivation	O
or	O
copper	O
treatment	O
.	O
To	O
understand	O
the	O
toxicity	O
of	O
nonylphenol	B-Hazardous
diethoxylate	I-Hazardous
,	O
we	O
investigated	O
the	O
effects	O
of	O
NP2	B-Hazardous
EO	I-Hazardous
on	O
apoptosis	B-Cell
induced	O
by	O
serum	B-Body
deprivation	O
and	O
copper	O
by	O
using	O
PC12	B-Cell
cell	I-Cell
system	I-Cell
.	O
Nonylphenol	B-Hazardous
diethoxylate	I-Hazardous
itself	O
showed	O
no	O
toxicity	O
and	O
recovered	O
cell	B-Cell
viability	I-Cell
from	O
apoptosis	B-Cell
.	O
In	O
addition,	O
nonylphenol	B-Hazardous
diethoxylate	I-Hazardous
decreased	O
DNA	B-Molecular
fragmentation	I-Molecular
caused	O
by	O
apoptosis	B-Cell
in	O
PC12	B-Cell
cells	I-Cell
.	O
This	O
phenomenon	O
was	O
confirmed	O
after	O
treating	O
apoptotic	O
PC12	B-Cell
cells	I-Cell
with	O
nonylphenol	B-Hazardous
diethoxylate	I-Hazardous
,	O
whereas	O
the	O
cytochrome	O
c	O
release	O
into	O
the	O
cytosol	B-Cell
decreased	O
as	O
compared	O
to	O
that	O
in	O
apoptotic	B-Cell
cells	I-Cell
not	O
treated	O
with	O
nonylphenol	B-Hazardous
diethoxylate	I-Hazardous
s.	O
Furthermore,	O
Bax	O
contents	O
in	O
apoptotic	B-Cell
cells	I-Cell
were	O
reduced	O
after	O
exposure	O
to	O
nonylphenol	B-Hazardous
diethoxylate	I-Hazardous
.	O
Thus,	O
nonylphenol	B-Hazardous
diethoxylate	I-Hazardous
has	O
the	O
opposite	O
effect	O
on	O
apoptosis	B-Cell
in	O
PC12	B-Cell
cells	I-Cell
compared	O
to	O
nonylphenol	B-Hazardous
,	O
which	O
enhances	O
apoptosis	B-Cell
induced	O
by	O
serum	B-Body
deprivation	O
.	O
The	O
difference	O
in	O
structure	O
of	O
the	O
two	O
compounds	B-Chemical
is	O
hypothesized	O
to	O
be	O
responsible	O
for	O
this	O
phenomenon	O
.	O
These	O
results	B-Finding
indicated	O
that	O
nonylphenol	B-Hazardous
diethoxylate	I-Hazardous
has	O
capability	O
to	O
affect	O
cell	B-Cell
differentiation	I-Cell
and	O
development	B-Physiologic
and	O
has	O
potentially	O
harmful	B-Injury
effect	I-Injury
on	O
organisms	O
because	O
of	O
its	O
unexpected	O
impact	O
on	O
apoptosis	B-Cell
.	O
©	O
2015	O
Wiley	O
Periodicals,	O
Inc.	O
Environ	O
Toxicol	O
31:	O
1389-1398,	O
2016.	O

==DOCSTART==	
Prevascularized	O
silicon	O
membranes	O
for	O
the	O
enhancement	O
of	O
transport	O
to	O
implanted	B-Finding
medical	I-Finding
devices	I-Finding
Recent	O
advances	O
in	O
drug	B-Medical
delivery	I-Medical
and	O
sensing	O
devices	O
for	O
in	O
situ	O
applications	O
are	O
limited	O
by	O
the	O
diffusion	O
-limiting	O
foreign	B-Finding
body	I-Finding
response	I-Finding
of	O
fibrous	O
encapsulation	O
.	O
In	O
this	O
study,	O
we	O
fabricated	O
prevascularized	O
synthetic	O
device	O
ports	O
to	O
help	O
mitigate	O
this	O
limitation	O
.	O
Membranes	O
with	O
rectilinear	O
arrays	O
of	O
square	O
pores	O
with	O
widths	O
ranging	O
from	O
40	O
to	O
200	O
μm	O
were	O
created	O
using	O
materials	O
(50	O
μm	O
thick	O
double-sided	O
polished	O
silicon)	O
and	O
processes	O
(	O
photolithography	O
and	O
directed	O
reactive	O
ion	O
etching	O
)	O
common	O
in	O
the	O
manufacturing	O
of	O
microfabricated	O
sensors	O
.	O
Vascular	B-Cell
endothelial	I-Cell
cells	I-Cell
responded	O
to	O
membrane	O
geometry	O
by	O
either	O
forming	O
vascular	B-Body
tubes	I-Body
that	O
extended	O
through	O
the	O
pore	O
or	O
completely	O
filling	O
membrane	O
pores	O
after	O
4	O
days	O
in	O
culture	B-Laboratory
.	O
Although	O
tube	O
formation	O
began	O
to	O
predominate	O
overgrowth	B-Finding
around	O
75	O
μm	O
and	O
continued	O
to	O
increase	O
at	O
even	O
larger	O
pore	O
sizes	O
,	O
tubes	O
formed	O
at	O
these	O
large	O
pore	O
sizes	O
were	O
not	O
completely	O
round	O
and	O
had	O
relatively	O
thin	O
walls	O
.	O
Thus,	O
the	O
optimum	O
range	O
of	O
pore	O
size	O
for	O
prevascularization	O
of	O
these	O
membranes	O
was	O
estimated	O
to	O
be	O
75-100	O
μm.	O
This	O
study	O
lays	O
the	O
foundation	O
for	O
creating	O
a	O
prevascularized	O
port	O
that	O
can	O
be	O
used	O
to	O
reduce	O
fibrous	O
encapsulation	O
and	O
thus	O
enhance	O
diffusion	O
to	O
implanted	B-Finding
medical	I-Finding
devices	I-Finding
and	O
sensors	O
.	O
©	O
2015	O
Wiley	O
Periodicals,	O
Inc.	O
J	O
Biomed	O
Mater	O
Res	O
Part	O
B:	O
Appl	O
Biomater,	O
104B:	O
1602-1609,	O
2016.	O
	
==DOCSTART==	
Seated	B-Finding
maximum	O
flexion	B-Organ
:	O
An	O
alternative	O
to	O
standing	O
maximum	O
flexion	B-Organ
for	O
determining	O
presence	O
of	O
flexion	B-Organ
-	O
relaxation	O
?	O
The	O
flexion	B-Organ
-	O
relaxation	O
phenomenon	O
(	O
FRP	O
)	O
in	O
standing	O
is	O
a	O
specific	O
and	O
sensitive	O
diagnostic	B-Diagnostic
tool	I-Diagnostic
for	O
low	B-Sign
back	I-Sign
pain	I-Sign
.	O
Seated	B-Organ
flexion	I-Organ
as	O
an	O
alternative	O
could	O
be	O
beneficial	O
for	O
certain	O
populations	O
,	O
yet	O
the	O
behavior	O
of	O
the	O
trunk	B-Tissue
extensors	I-Tissue
during	O
seated	B-Finding
maximum	O
flexion	B-Organ
compared	O
to	O
standing	O
flexion	B-Organ
remains	O
unclear.	O
Compare	O
FRP	O
occurrences	O
and	O
spine	B-Body
angles	O
between	O
seated	B-Finding
and	O
standing	O
flexion	B-Organ
postures	O
in	O
three	O
levels	O
of	O
the	O
erector	B-Body
spinae	I-Body
muscles	I-Body
.	O
Thirty-one	O
participants	O
free	O
of	O
back	B-Sign
pain	I-Sign
performed	O
seated	B-Finding
and	O
standing	O
maximum	O
trunk	B-Body
flexion	B-Organ
.	O
Electromyographical	O
signals	O
were	O
recorded	O
from	O
the	O
bilateral	B-Body
lumbar	I-Body
(L3)	I-Body
,	O
lower-thoracic	B-Body
(T9)	I-Body
,	O
and	O
upper-thoracic	B-Body
(T4)	I-Body
erector	B-Body
spinae	I-Body
and	O
assessed	O
for	O
the	O
occurrence	O
of	O
FRP	O
.	O
Spine	O
angles	O
corresponding	O
to	O
FRP	O
onset	O
and	O
cessation	O
were	O
determined,	O
and	O
FRP	O
occurrences	O
and	O
angles	O
were	O
compared	O
between	O
posture	O
and	O
muscle	B-Tissue
.	O
FRP	O
occurrence	O
was	O
similar	O
in	O
standing	O
and	O
seated	B-Finding
maximum	O
flexion	B-Organ
across	O
all	O
muscles	B-Tissue
,	O
with	O
the	O
lumbar	B-Tissue
muscles	I-Tissue
showing	O
the	O
greatest	O
consistency	O
.	O
Standing	O
FRP	O
onset	O
and	O
cessation	O
angles	O
were	O
consistently	O
greater	O
than	O
the	O
corresponding	O
seated	B-Finding
FRP	O
angles.	O
Considering	O
the	O
similar	O
number	O
of	O
FRP	O
occurrences,	O
seated	B-Finding
maximum	O
flexion	B-Organ
may	O
constitute	O
an	O
objective	O
criterion	O
for	O
low	B-Sign
back	I-Sign
pain	I-Sign
diagnosis	B-Finding
.	O
Future	O
work	O
should	O
seek	O
to	O
confirm	O
the	O
utility	O
of	O
this	O
test	O
in	O
individuals	O
with	O
low	B-Sign
back	I-Sign
pain	I-Sign
.	O
	
==DOCSTART==	
The	O
Relationship	O
Between	O
Distance	O
and	O
Post-operative	B-Finding
Visit	O
Attendance	O
Following	O
Medical	O
Male	B-Therapeutic
Circumcision	I-Therapeutic
in	O
Nyanza	O
Province	O
,	O
Kenya	O
To	O
date,	O
there	O
is	O
no	O
research	O
on	O
voluntary	O
medical	O
male	B-Therapeutic
circumcision	I-Therapeutic
(	O
VMMC	B-Therapeutic
)	O
catchment	O
areas	O
or	O
the	O
relationship	O
between	O
distance	O
to	O
a	O
VMMC	B-Therapeutic
facility	O
and	O
attendance	O
at	O
a	O
post-operative	B-Finding
follow-up	O
visit	O
.	O
We	O
analyzed	O
data	O
from	O
a	O
randomly	O
selected	O
subset	O
of	O
males	O
self-seeking	B-Therapeutic
circumcision	I-Therapeutic
at	O
one	O
of	O
16	O
participating	O
facilities	O
in	O
Nyanza	O
Province	O
,	O
Kenya	O
between	O
2008	O
and	O
2010.	O
Among	O
1437	O
participants	O
,	O
46.7	O
%	O
attended	O
follow-up	O
.	O
The	O
median	O
distance	O
from	O
residence	O
to	O
utilized	O
facility	O
was	O
2.98	O
km	O
(	O
IQR	O
1.31-5.38).	O
Nearly	O
all	O
participants	O
(98.8	O
%)	O
lived	O
within	O
5	O
km	O
from	O
a	O
facility,	O
however,	O
26.3	O
%	O
visited	O
a	O
facility	O
more	O
than	O
5	O
km	O
away.	O
Stratified	O
results	O
demonstrated	O
that	O
among	O
those	O
utilizing	O
fixed	O
facilities,	O
greater	O
distance	O
was	O
associated	O
with	O
higher	O
odds	O
of	O
follow-up	O
non-attendance	O
(	O
OR	O
5.01-10km	O
vs.	O
0-1km	O
=	O
1.71,	O
95	O
%	O
CI	O
1.08,	O
2.70,	O
p	O
=	O
0.02;	O
OR	O
>10km	O
vs.	O
0-1	O
km	O
=	O
2.80,	O
95	O
%	O
CI	O
1.26,	O
6.21,	O
p	O
=	O
0.01),	O
adjusting	O
for	O
age	O
and	O
district	O
of	O
residence	O
.	O
We	O
found	O
5	O
km	O
marked	O
the	O
threshold	O
distance	O
beyond	O
which	O
follow-up	O
attendance	O
significantly	O
dropped	O
.	O
These	O
results	O
demonstrate	O
distance	O
is	O
an	O
important	O
predictor	O
of	O
attending	O
follow-up	O
,	O
and	O
this	O
relationship	O
appears	O
to	O
be	O
modified	O
by	O
facility	O
type	O
.	O
	
==DOCSTART==	
Promoting	O
lifestyle	O
behaviour	O
change	O
and	O
well-being	B-Finding
in	O
hospital	O
patients	O
:	O
a	O
pilot	O
study	O
of	O
an	O
evidence-based	O
psychological	O
intervention	B-Therapeutic
Lifestyle	O
risk	O
behaviours	O
show	O
an	O
inverse	O
social	O
gradient	O
,	O
clustering	O
in	O
vulnerable	O
groups	O
.	O
We	O
designed	O
and	O
piloted	O
an	O
intervention	B-Therapeutic
to	O
address	O
barriers	O
to	O
lifestyle	O
behaviour	O
change	O
among	O
hospital	O
patients	O
.	O
We	O
designed	O
our	O
intervention	B-Therapeutic
using	O
effective	O
components	O
of	O
behaviour	O
change	O
interventions	B-Therapeutic
informed	O
by	O
psychological	O
theory	O
.	O
Delivered	O
by	O
a	O
health	O
psychologist	O
based	O
at	O
the	O
Royal	O
Free	O
London	O
NHS	O
Foundation	O
Trust	O
,	O
the	O
4-week	O
intervention	B-Therapeutic
included	O
detailed	O
baseline	O
assessment	O
,	O
personalized	O
goal	B-Therapeutic
setting	I-Therapeutic
,	O
psychological	B-Mental
skills	I-Mental
development	I-Mental
,	O
motivation	O
support	O
and	O
referral	O
to	O
community	O
services	O
.	O
Primary	O
outcomes	O
were	O
feasibility	O
and	O
patient	O
acceptability	O
.	O
We	O
also	O
evaluated	O
changes	O
to	O
health	O
and	O
well-being	B-Finding
.	O
From	O
1	O
July	O
2013	O
to	O
31	O
September	O
2014,	O
686	O
patients	O
were	O
referred	O
,	O
338	O
(49.3%)	O
attended	O
a	O
first	O
appointment	O
and	O
172	O
(25.1%)	O
completed	O
follow-up	O
.	O
Furthermore,	O
72.1%	O
of	O
attenders	O
were	O
female	O
with	O
the	O
median	O
age	O
55	O
years	O
and	O
poor	O
self-reported	O
baseline	O
health	O
.	O
After	O
4	O
weeks	O
,	O
self-efficacy	B-Mental
,	O
health	O
and	O
well-being	O
scores	O
significantly	B-Finding
improved	I-Finding
:	O
63%	O
of	O
lifestyle	B-Finding
goals	I-Finding
and	O
89%	O
of	O
health	O
management	O
goals	O
were	O
fully	O
achieved	B-Finding
;	O
58%	O
of	O
referrals	O
to	O
community	O
lifestyle	O
behaviour	O
change	O
services	O
and	O
79%	O
of	O
referrals	O
to	O
other	O
services	O
(e.g.	O
Citizen's	O
Advice	O
Bureau	O
)	O
were	O
accepted;	O
99%	O
were	O
satisfied	O
/	O
very	B-Finding
satisfied	I-Finding
with	O
the	O
service	O
.	O
Our	O
hospital-based	B-Therapeutic
intervention	I-Therapeutic
was	O
feasible,	O
acceptable	O
and	O
showed	O
preliminary	B-Finding
health	I-Finding
and	I-Finding
well-being	I-Finding
gains	I-Finding
.	O
	
==DOCSTART==	
The	O
Impact	O
of	O
Deployment	O
on	O
Parental	O
,	O
Family	O
and	O
Child	O
Adjustment	O
in	O
Military	O
Families	O
Since	O
9/11,	O
military	O
service	O
in	O
the	O
United	O
States	O
has	O
been	O
characterized	O
by	O
wartime	O
deployments	O
and	O
reintegration	O
challenges	O
that	O
contribute	O
to	O
a	O
context	O
of	O
stress	B-Finding
for	O
military	O
families	O
.	O
Research	O
indicates	O
the	O
negative	B-Finding
impact	I-Finding
of	O
wartime	O
deployment	O
on	O
the	O
well	O
being	O
of	O
service	O
members	O
,	O
military	O
spouses	O
,	O
and	O
children	O
.	O
Yet,	O
few	O
studies	O
have	O
considered	O
how	O
parental	O
deployments	O
may	O
affect	O
adjustment	O
in	O
young	O
children	O
and	O
their	O
families	O
.	O
Using	O
deployment	O
records	O
and	O
parent	O
-	O
reported	O
measures	O
from	O
primary	O
caregiving	O
(N	O
=	O
680)	O
and	O
military	O
(n	O
=	O
310)	O
parents	O
,	O
we	O
examined	O
the	O
influence	O
of	O
deployment	O
on	O
adjustment	O
in	O
military	O
families	O
with	O
children	O
ages	O
0-10	O
years.	O
Greater	O
deployment	O
exposure	O
was	O
related	O
to	O
impaired	O
family	O
functioning	O
and	O
marital	B-Finding
instability	B-Finding
.	O
Parental	O
depressive	B-Mental
and	O
posttraumatic	B-Mental
stress	I-Mental
symptoms	I-Mental
were	O
associated	O
with	O
impairments	O
in	O
social	O
emotional	B-Finding
adjustment	O
in	O
young	O
children	O
,	O
increased	O
anxiety	B-Finding
in	O
early	O
childhood	O
,	O
and	O
adjustment	O
problems	O
in	O
school-age	O
children	O
.	O
Conversely,	O
parental	O
sensitivity	B-Mental
was	O
associated	O
with	O
improved	O
social	O
and	O
emotional	B-Finding
outcomes	I-Finding
across	O
childhood	O
.	O
These	O
findings	B-Finding
provide	O
guidance	O
to	O
developing	O
preventive	O
approaches	O
for	O
military	O
families	O
with	O
young	O
children	O
.	O
	
==DOCSTART==	
Combining	O
electrostatic	O
powder	O
with	O
an	O
insecticide	B-Hazardous
:	O
effect	O
on	O
stored	O
-	O
product	O
beetles	B-Eukaryote
and	O
on	O
the	O
commodity	O
The	O
opportunity	O
to	O
reduce	O
the	O
amount	O
of	O
pirimiphos-methyl	O
applied	O
to	O
grain	O
by	O
formulating	O
it	O
in	O
an	O
electrostatic	O
powder	O
was	O
investigated.	O
The	O
insecticidal	B-Hazardous
efficacy	O
of	O
pirimiphos-methyl	O
in	O
EC	B-Hazardous
formulation	I-Hazardous
or	O
formulated	O
using	O
electrostatic	O
powder	O
(	O
EP	O
)	O
as	O
an	O
inert	O
carrier	O
was	O
investigated	O
against	O
Sitophilus	B-Eukaryote
oryzae	I-Eukaryote
(L.),	O
Oryzaephilus	B-Eukaryote
surinamensis	I-Eukaryote
(L.),	O
Rhyzopertha	B-Eukaryote
dominica	I-Eukaryote
(F.)	O
and	O
Tribolium	B-Eukaryote
confusum	I-Eukaryote
Jacquelin	I-Eukaryote
du	I-Eukaryote
Val	I-Eukaryote
.	O
Furthermore,	O
the	O
adhesive	O
properties	O
of	O
EP	O
to	O
rice	O
,	O
corn	O
and	O
wheat	O
,	O
together	O
with	O
the	O
effect	O
on	O
bulk	O
density	O
and	O
bread	O
-	O
and	O
pasta	O
-	O
making	O
properties	O
,	O
were	O
investigated.	O
The	O
results	O
showed	O
that	O
pirimiphos-methyl	O
formulated	O
with	O
EP	O
provided	O
better	O
efficacy	O
against	O
adults	B-Eukaryote
when	O
compared	O
with	O
EC	B-Hazardous
formulation	I-Hazardous
for	O
O.	B-Eukaryote
surinamensis	I-Eukaryote
and	O
T.	B-Eukaryote
confusum	I-Eukaryote
,	O
but	O
there	O
was	O
no	O
difference	O
for	O
R.	B-Eukaryote
dominica	I-Eukaryote
.	O
Progeny	O
production	O
was	O
consistently	O
lower	O
in	O
grain	O
treated	B-Therapeutic
with	I-Therapeutic
the	O
EP	O
formulation	O
than	O
in	O
grain	O
treated	B-Therapeutic
with	I-Therapeutic
the	O
EC	B-Hazardous
.	O
Tests	O
showed	O
that	O
EP	O
adhered	O
to	O
the	O
kernels	O
for	O
longer	O
on	O
hard	O
wheat	O
than	O
on	O
maize	O
or	O
rice	O
.	O
In	O
most	O
commodities	O
,	O
EP	O
did	O
not	O
alter	O
the	O
bulk	O
density	O
.	O
Finally,	O
the	O
addition	O
of	O
EP	O
did	O
not	O
affect	O
flour	O
-	O
and	O
bread	O
-	O
making	O
properties	O
,	O
nor	O
the	O
pasta	O
-making	O
properties	O
.	O
The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
an	O
EP	O
could	O
be	O
used	O
to	O
reduce	O
the	O
amount	O
of	O
pirimiphos-methyl	O
applied	O
to	O
grain	O
for	O
effective	O
pest	O
control	O
,	O
with	O
no	O
detrimental	O
effects	O
on	O
grain	O
quality	O
.	O
©	O
	
==DOCSTART==	
2016	O
Society	O
of	O
Chemical	O
Industry.	O
	
==DOCSTART==	
Radiofrequency	B-Therapeutic
ablation	I-Therapeutic
of	O
posteroseptal	B-Body
accessory	I-Body
pathways	I-Body
associated	O
with	O
coronary	O
sinus	O
diverticula	O
Posteroseptal	B-Body
accessory	I-Body
pathways	I-Body
may	O
be	O
associated	O
with	O
a	O
coronary	O
sinus	O
(CS)	O
diverticulum.	O
Our	O
purpose	O
was	O
to	O
describe	O
the	O
clinical	O
characteristics	O
,	O
mapping	O
and	O
ablation	B-Therapeutic
of	I-Therapeutic
these	I-Therapeutic
pathways	I-Therapeutic
.	O
This	O
was	O
a	O
retrospective	O
study	O
of	O
all	O
patients	O
who	O
underwent	O
ablation	B-Therapeutic
of	O
posteroseptal	B-Body
accessory	I-Body
pathways	I-Body
in	O
a	O
single	O
centre	O
.	O
Patients	O
with	O
a	O
diverticulum	O
of	O
the	O
CS	O
or	O
one	O
of	O
its	O
tributaries	B-Body
were	O
included	O
in	O
group	O
I	O
,	O
while	O
the	O
other	O
patients	O
formed	O
group	O
II	O
.	O
Clinical	O
presentation	O
,	O
ablation	B-Therapeutic
procedure	I-Therapeutic
and	O
outcome	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O
A	O
total	O
of	O
51	O
patients	O
were	O
included,	O
16	O
in	O
group	O
I	O
and	O
35	O
in	O
group	O
II	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
age	O
or	O
sex	O
distribution	O
.	O
Atrial	B-Disease
fibrillation	I-Disease
(	O
AF	B-Disease
)	O
and	O
previous	O
unsuccessful	O
ablation	B-Therapeutic
were	O
more	O
common	O
in	O
group	O
I	O
.	O
A	O
negative	B-Finding
delta	B-Finding
wave	I-Finding
in	O
lead	O
II	O
was	O
the	O
ECG	B-Diagnostic
finding	B-Finding
with	O
best	O
sensitivity	O
and	O
specificity	O
for	O
the	O
presence	O
of	O
a	O
diverticulum	B-Pathologic
.	O
A	O
pathway	B-Body
potential	O
was	O
common	O
at	O
the	O
successful	O
site	O
in	O
group	O
I	O
,	O
and	O
the	O
interval	O
between	O
local	B-Diagnostic
ventricular	I-Diagnostic
electrogram	I-Diagnostic
and	O
delta	B-Finding
wave	I-Finding
onset	O
was	O
shorter	O
(19.5	O
±	O
8	O
vs	O
33.1	O
±	O
7.6	O
ms,	O
p	O
<	O
0.001).	O
There	O
was	O
a	O
trend	O
toward	O
lower	O
procedural	O
success	O
rate	O
and	O
higher	O
recurrence	O
rate	O
in	O
group	O
I	O
,	O
although	O
this	O
was	O
not	O
significant	O
.	O
CS	O
diverticula	O
should	O
be	O
suspected	O
in	O
patients	O
with	O
manifest	O
posteroseptal	B-Body
accessory	I-Body
pathways	I-Body
who	O
have	O
a	O
previous	O
failed	O
ablation	B-Therapeutic
,	O
documented	O
AF	B-Disease
or	O
typical	O
electrocardiographic	B-Finding
	
==DOCSTART==	
signs	I-Finding
.	O
A	O
discrete	O
potential	O
is	O
frequently	O
seen	O
at	O
the	O
successful	O
site,	O
but	O
the	O
local	B-Diagnostic
ventricular	I-Diagnostic
electrogram	I-Diagnostic
is	O
not	O
as	O
early	O
as	O
in	O
other	O
accessory	B-Body
pathways	I-Body
.	O
	
==DOCSTART==	
Association	O
of	O
RBP4	O
levels	O
with	O
increased	O
arterial	B-Physiologic
stiffness	I-Physiologic
in	O
adolescents	O
with	O
family	B-Finding
history	I-Finding
of	I-Finding
type	I-Finding
2	I-Finding
diabetes	I-Finding
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
impact	O
of	O
family	B-Finding
history	I-Finding
of	I-Finding
type	I-Finding
2	I-Finding
diabetes	I-Finding
(	O
FH2D	B-Finding
)	O
on	O
arterial	B-Physiologic
stiffness	I-Physiologic
in	O
young	O
people	O
and	O
its	O
relationship	O
to	O
adipocytokines.	O
This	O
case-control	O
study	O
included	O
52	O
adolescents	O
(	O
male	O
/	O
female	O
28/24)	O
with	O
FH2D	B-Finding
(	O
FH2D+	B-Finding
)	O
and	O
40	O
adolescents	O
(	O
male	O
/	O
female	O
21/19)	O
without	O
FH2D	B-Finding
(	O
FH2D-	B-Finding
).	O
Anthropometric	O
measurements	O
,	O
including	O
height	O
,	O
weight	O
,	O
waist	O
circumference	O
(	O
WC	O
),	O
and	O
blood	B-Organism
pressure	I-Organism
,	O
were	O
obtained.	O
Blood	B-Body
samples	I-Body
were	O
collected,	O
fasting	B-Laboratory
plasma	I-Laboratory
glucose	I-Laboratory
(	O
FPG	B-Laboratory
),	O
serum	B-Laboratory
lipids	I-Laboratory
,	O
Retinol	O
Binding	O
Protein	O
4	O
(RBP4),	O
C	B-Laboratory
reactive	I-Laboratory
protein	I-Laboratory
(	O
CRP	B-Laboratory
),	O
adiponectin	B-Laboratory
and	O
visfatin	O
were	O
examined.	O
Brachial-ankle	O
pulse	O
wave	O
velocity	O
(	O
baPWV	O
)	O
was	O
used	O
to	O
evaluate	O
arterial	B-Physiologic
stiffness	I-Physiologic
.	O
Visceral	O
fat	O
area	O
(	O
VFA	O
)	O
was	O
measured	O
by	O
computerized	B-Diagnostic
tomography	I-Diagnostic
.	O
Compared	O
with	O
FH2D-	B-Finding
group	O
,	O
FH2D+	B-Finding
group	O
had	O
a	O
significantly	O
higher	O
oral	B-Laboratory
glucose	I-Laboratory
tolerance	I-Laboratory
test	I-Laboratory
(OGTT)	I-Laboratory
2-hour	I-Laboratory
insulin	I-Laboratory
,	O
RBP4	O
and	O
baPWV	O
levels,	O
a	O
lower	O
adiponectin	B-Laboratory
and	O
glucose	O
infusing	O
rate	O
(	O
GIR	O
)	O
(P<0.05).	O
BaPWV	O
was	O
positively	O
correlated	O
with	O
age	O
,	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
),	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
),	O
2-hour	B-Laboratory
(OGTT)	I-Laboratory
insulin	I-Laboratory
,	O
RBP4,	O
and	O
VFA	O
,	O
and	O
negatively	O
correlated	O
with	O
GIR	O
in	O
FH2D+	B-Finding
group	O
.	O
After	O
multivariate	O
analysis	O
,	O
age	O
,	O
SBP	O
,	O
RBP4	O
and	O
VFA	O
maintained	O
an	O
independent	O
association	O
with	O
baPWV	O
in	O
FH2D+	B-Finding
group	O
(P<0.05),	O
while	O
only	O
age	O
,	O
SBP	O
,	O
and	O
VFA	O
	
==DOCSTART==	
were	O
independent	O
predictors	O
of	O
baPWV	O
in	O
FH2D-	B-Finding
group	O
(P<0.05).	O
These	O
findings	B-Finding
led	O
to	O
the	O
conclusion	O
that	O
RBP4	O
level	O
was	O
associated	O
with	O
increased	O
arterial	B-Physiologic
stiffness	I-Physiologic
in	O
young	O
subjects	O
with	O
family	B-Finding
history	I-Finding
of	I-Finding
type	I-Finding
2	I-Finding
diabetes	I-Finding
.	O
	
==DOCSTART==	
EZH2	O
and	O
ZFX	O
oncogenes	O
in	O
malignant	O
behaviour	O
of	O
parathyroid	B-Neoplastic
neoplasms	I-Neoplastic
Several	O
studies	O
reported	O
somatic	B-Cell
mutations	I-Cell
of	O
many	O
genes	O
(	O
MEN1	O
,	O
CTNNB1	O
,	O
CDKIs	O
and	O
others)	O
in	O
parathyroid	B-Neoplastic
adenoma	I-Neoplastic
,	O
although	O
with	O
different	O
prevalence	O
.	O
Recently,	O
activating	O
mutations	B-Genetic
of	O
the	O
EZH2	O
and	O
ZFX	O
oncogenes	O
were	O
identified	O
in	O
benign	O
parathyroid	B-Neoplastic
adenoma	I-Neoplastic
by	O
whole	B-Molecular
exome	I-Molecular
sequencing	I-Molecular
.	O
The	O
same	O
mutations	B-Genetic
had	O
been	O
found	O
in	O
blood	B-Body
and	O
ovary	B-Body
malignant	B-Neoplastic
tumours	I-Neoplastic
.	O
On	O
one	O
hand,	O
this	O
result	O
raised	O
the	O
hypothesis	O
that	O
these	O
oncogenes	O
may	O
play	O
a	O
role	O
in	O
the	O
onset	O
of	O
parathyroid	B-Neoplastic
tumour	I-Neoplastic
,	O
but	O
it	O
would	O
also	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
malignant	O
,	O
rather	O
benign	O
,	O
parathyroid	B-Neoplastic
neoplasm	I-Neoplastic
.	O
Our	O
aim	O
was	O
to	O
verify	O
the	O
occurrence	O
of	O
selected	O
mutations	B-Genetic
of	O
the	O
EZH2	O
and	O
ZFX	O
genes	O
in	O
an	O
Italian	O
cohort	O
of	O
23	O
sporadic	O
parathyroid	B-Neoplastic
carcinomas	I-Neoplastic
,	O
12	O
atypical	O
and	O
45	O
typical	O
adenomas	B-Neoplastic
.	O
DNA	O
was	O
extracted	B-Therapeutic
from	O
paraffin-embedded	B-Tissue
tissues	I-Tissue
,	O
PCR	B-Molecular
amplified	O
and	O
directly	O
sequenced	O
.	O
No	B-Finding
mutations	B-Genetic
were	O
detected	B-Finding
in	O
the	O
coding	O
sequence	O
and	O
boundaries	O
of	O
both	O
genes	O
in	O
any	O
of	O
the	O
samples	O
.	O
Two	O
polymorphisms	B-Genetic
of	O
the	O
EZH2	O
gene	O
were	O
identified	O
with	O
different	O
prevalence	O
:	O
the	O
rs2072407	O
variant	O
was	O
present	B-Finding
in	O
the	O
30	O
%	O
of	O
the	O
samples	O
,	O
in	O
keeping	O
with	O
the	O
overall	O
frequency	O
in	O
larger	O
populations	O
,	O
while	O
the	O
rs78589034	O
variant	O
,	O
located	O
close	O
to	O
the	O
5'	B-Nucleic
end	I-Nucleic
of	O
the	O
exon	O
16,	O
was	O
detected	B-Finding
in	O
only	O
one	O
proband	O
with	O
familial	O
isolated	O
hyperparathyroidism	B-Disease
;	O
we	O
investigated	O
the	O
possible	O
outcome	O
on	O
the	O
splicing	B-Genetic
process	I-Genetic
.	O
EZH2	O
and	O
ZFX	O
genes	O
do	O
not	O
	
==DOCSTART==	
seem	O
to	O
have	O
an	O
impact	O
on	O
the	O
onset	O
of	O
most	O
parathyroid	B-Neoplastic
tumours	I-Neoplastic
,	O
both	O
benign	O
and	O
malignant	O
,	O
though	O
further	O
studies	O
on	O
larger	O
cohorts	O
of	O
different	O
ethnicity	O
are	O
needed.	O
	
==DOCSTART==	
The	O
effect	O
of	O
total	B-Therapeutic
hip	I-Therapeutic
arthroplasty	I-Therapeutic
on	O
sagittal	B-Body
spinal	O
-	O
pelvic-leg	B-Body
alignment	B-Finding
and	O
low	B-Sign
back	I-Sign
pain	I-Sign
in	O
patients	O
with	O
severe	O
hip	B-Disease
osteoarthritis	I-Disease
Sagittal	B-Body
spinopelvic	B-Body
malalignment	B-Pathologic
has	O
been	O
reported	O
in	O
spinal	B-Disease
disorders	I-Disease
such	O
as	O
low	B-Sign
back	I-Sign
pain	I-Sign
(	O
LBP	B-Sign
),	O
and	O
restoration	O
of	O
normal	O
alignment	B-Finding
is	O
targeted	O
when	O
treating	B-Therapeutic
these	O
disorders	B-Disease
.	O
Abnormal	B-Finding
sagittal	B-Body
spinal	O
-	O
pelvic-leg	B-Body
alignment	B-Finding
has	O
been	O
reported	O
in	O
patients	O
with	O
severe	O
hip	B-Disease
osteoarthritis	I-Disease
(	O
OA	B-Disease
),	O
who	O
have	O
a	O
high	O
prevalence	O
of	O
associated	O
LBP	B-Sign
.	O
This	O
prospective	O
longitudinal	O
study	O
aimed	O
to	O
investigate	O
changes	O
in	O
sagittal	B-Body
spinal	O
-	O
pelvic-leg	B-Body
alignment	B-Finding
after	O
total	B-Therapeutic
hip	I-Therapeutic
arthroplasty	I-Therapeutic
(	O
THA	B-Therapeutic
)	O
in	O
patients	O
with	O
severe	O
hip	B-Disease
OA	I-Disease
,	O
and	O
whether	O
these	O
changes	O
contribute	O
to	O
LBP	B-Sign
relief	B-Finding
.	O
Patients	O
undergoing	O
primary	O
THA	B-Therapeutic
due	O
to	O
severe	O
unilateral	O
hip	B-Disease
OA	I-Disease
were	O
recruited.	O
Physical	O
examination	O
and	O
X-ray	B-Medical
films	I-Medical
were	O
taken	O
to	O
rule	O
out	O
any	O
spinal	B-Disease
disorder	I-Disease
.	O
Sagittal	B-Body
alignment	B-Finding
of	O
pelvis	B-Body
,	O
hip	B-Body
,	O
and	O
spine	B-Body
was	O
analyzed	O
on	O
lateral	B-Diagnostic
radiographs	I-Diagnostic
taken	O
before	O
(	O
baseline	O
)	O
and	O
1	O
year	O
after	O
(	O
follow-up	O
)	O
THA	B-Therapeutic
.	O
Functional	B-Medical
instruments	I-Medical
were	O
completed	O
by	O
patients	O
including:	O
visual	B-Diagnostic
analog	I-Diagnostic
scale	I-Diagnostic
(	O
VAS	B-Diagnostic
)	O
for	O
LBP	B-Sign
,	O
Roland-Morris	O
Disability	O
Questionnaire	O
(	O
RMDQ	O
),	O
and	O
Harris	B-Finding
Hip	I-Finding
Score	I-Finding
(	O
HHS	B-Finding
).	O
Comparisons	O
were	O
carried	O
out	O
at	O
baseline	O
and	O
follow-up	O
,	O
and	O
between	O
patients	O
with	O
and	O
without	O
LBP	B-Sign
.	O
The	O
recruited	O
69	O
patients	O
showed	O
significantly	O
reduced	O
hip	B-Finding
flexion	I-Finding
and	O
improved	O
global	B-Finding
spinal	I-Finding
balance	I-Finding
at	O
follow-up	O
compared	O
with	O
baseline	O
.	O
LBP	B-Sign
was	O
reported	O
by	O
39	O
patients	O
(56.5	O
%)	O
before	O
surgery	O
;	O
at	O
follow-up	O
,	O
17	O
	
==DOCSTART==	
reported	O
complete	O
resolution	O
,	O
while	O
22	O
reported	O
significant	O
relief	B-Finding
.	O
Significant	O
decreases	O
in	O
VAS	O
and	O
RMDQ	O
scores	O
in	O
lumbar	B-Body
spine	I-Body
and	O
increase	O
in	O
hip	B-Body
HHS	B-Finding
were	O
observed.	O
THA	B-Therapeutic
in	O
patients	O
with	O
severe	O
hip	B-Disease
OA	I-Disease
could	O
help	O
correct	O
abnormal	O
sagittal	B-Body
spinal	O
-	O
pelvic-leg	B-Body
alignment	B-Finding
and	O
relieve	O
comorbid	B-Finding
LBP	B-Sign
.	O
Improvements	O
in	O
hip	B-Finding
flexion	I-Finding
and	O
global	O
spinal	O
balance	B-Organism
might	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
LBP	B-Sign
relief	B-Finding
.	O
	
==DOCSTART==	
Beyond	O
neutral	O
and	O
forbidden	O
links	O
:	O
morphological	O
matches	O
and	O
the	O
assembly	O
of	O
mutualistic	O
hawkmoth	B-Eukaryote
-	O
plant	O
networks	O
A	O
major	O
challenge	O
in	O
evolutionary	O
ecology	O
is	O
to	O
understand	O
how	O
co-evolutionary	O
processes	O
shape	O
patterns	O
of	O
interactions	O
between	O
species	O
at	O
community	O
level	O
.	O
Pollination	B-Organism
of	O
flowers	O
with	O
long	O
corolla	O
tubes	O
by	O
long-tongued	B-Eukaryote
hawkmoths	I-Eukaryote
has	O
been	O
invoked	O
as	O
a	O
showcase	O
model	B-Research
of	O
co-evolution	B-Genetic
.	O
Recently,	O
optimal	O
foraging	O
models	B-Research
have	O
predicted	O
that	O
there	O
might	O
be	O
a	O
close	O
association	O
between	O
mouthparts'	O
length	O
and	O
the	O
corolla	O
depth	O
of	O
the	O
visited	O
flowers	O
,	O
thus	O
favouring	O
trait	O
convergence	O
and	O
specialization	O
at	O
community	O
level.	O
Here,	O
we	O
assessed	O
whether	O
hawkmoths	B-Eukaryote
more	O
frequently	O
pollinate	O
plants	O
with	O
floral	O
tube	O
lengths	O
similar	O
to	O
their	O
proboscis	B-Eukaryote
lengths	O
(	O
morphological	O
match	O
hypothesis	O
)	O
against	O
abundance	O
-based	O
processes	O
(	O
neutral	O
hypothesis	O
)	O
and	O
ecological	O
trait	O
mismatches	O
constraints	O
(	O
forbidden	O
links	O
hypothesis	O
),	O
and	O
how	O
these	O
processes	O
structure	O
hawkmoth	B-Eukaryote
-	O
plant	O
mutualistic	O
networks	O
from	O
five	O
communities	O
in	O
four	O
biogeographical	O
regions	O
of	O
South	O
America	O
.	O
We	O
found	O
convergence	O
in	O
morphological	O
traits	O
across	O
the	O
five	O
communities	O
and	O
that	O
the	O
distribution	O
of	O
morphological	O
differences	O
between	O
hawkmoths	B-Eukaryote
and	O
plants	O
is	O
consistent	O
with	O
expectations	O
under	O
the	O
morphological	O
match	O
hypothesis	O
in	O
three	O
of	O
the	O
five	O
communities	O
.	O
In	O
the	O
two	O
remaining	O
communities	O
,	O
which	O
are	O
ecotones	O
between	O
two	O
distinct	O
biogeographical	O
areas	O
,	O
interactions	O
are	O
better	O
predicted	O
by	O
the	O
neutral	O
hypothesis	O
.	O
Our	O
findings	O
are	O
consistent	O
with	O
the	O
idea	O
that	O
diffuse	O
co-evolution	B-Genetic
drives	O
the	O
evolution	B-Genetic
of	O
extremely	O
long	B-Eukaryote
proboscises	I-Eukaryote
and	O
flower	O
tubes	O
,	O
and	O
highlight	O
the	O
importance	O
of	O
morphological	O
traits	O
,	O
beyond	O
the	O
forbidden	O
links	O
hypothesis	O
	
==DOCSTART==	
,	O
in	O
structuring	O
interactions	O
between	O
mutualistic	O
partners	O
,	O
revealing	O
that	O
the	O
role	O
of	O
niche-based	O
processes	O
can	O
be	O
much	O
more	O
complex	O
than	O
previously	O
known.	O
	
==DOCSTART==	
Impact	O
of	O
totally	O
laparoscopic	B-Diagnostic
combined	O
management	O
of	O
colorectal	B-Neoplastic
cancer	I-Neoplastic
with	O
synchronous	O
hepatic	B-Neoplastic
metastases	I-Neoplastic
on	O
severity	O
of	O
complications:	O
a	O
propensity-score	O
-based	O
analysis	O
Thanks	O
to	O
widespread	O
diffusion	O
of	O
minimally	B-Therapeutic
invasive	I-Therapeutic
approach	I-Therapeutic
in	O
the	O
setting	O
of	O
both	O
colorectal	B-Therapeutic
and	O
hepatic	B-Therapeutic
surgeries	I-Therapeutic
,	O
the	O
interest	O
in	O
combined	O
resections	O
for	O
colorectal	B-Neoplastic
cancer	I-Neoplastic
and	O
synchronous	O
liver	B-Neoplastic
metastases	I-Neoplastic
(	O
SCLM	B-Neoplastic
)	O
by	O
totally	B-Diagnostic
laparoscopic	I-Diagnostic
approach	I-Diagnostic
(	O
TLA	B-Diagnostic
)	O
has	O
increased.	O
Aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
outcome	O
of	O
combined	O
resections	O
for	O
SCLM	B-Neoplastic
performed	O
by	O
TLA	B-Diagnostic
or	O
by	O
open	O
approach,	O
in	O
a	O
propensity-score-based	O
study	O
.	O
All	O
25	O
patients	O
undergoing	O
combined	O
TLA	B-Diagnostic
for	O
SCLM	B-Neoplastic
at	O
San	O
Raffaele	O
Hospital	O
in	O
Milano	O
were	O
compared	O
in	O
a	O
case-matched	O
analysis	O
with	O
25	O
out	O
of	O
91	O
patients	O
undergoing	O
totally	B-Therapeutic
open	I-Therapeutic
approach	I-Therapeutic
(	O
TOA	O
group	O
).	O
Groups	O
were	O
matched	O
with	O
1:2	O
ratio	O
using	O
propensity	O
scores	O
based	O
on	O
covariates	O
representing	O
disease	O
severity.	O
Main	O
endpoints	O
were	O
postoperative	O
morbidity	O
and	O
long-term	O
outcome	O
.	O
The	O
Modified	O
Accordion	O
Severity	O
Grading	O
System	O
was	O
used	O
to	O
quantify	O
complications.	O
The	O
groups	O
resulted	O
comparable	O
in	O
terms	O
of	O
patients	O
and	O
disease	B-Pathologic
characteristics	I-Pathologic
.	O
The	O
TLA	O
group	O
,	O
as	O
compared	O
to	O
the	O
TOA	O
group	O
,	O
had	O
lower	O
blood	B-Pathologic
loss	I-Pathologic
(350	O
vs	O
600	O
mL),	O
shorter	O
postoperative	O
stay	O
(9	O
vs	O
12	O
days),	O
lower	O
postoperative	O
morbidity	O
index	O
(0.14	O
vs	O
0.20)	O
and	O
severity	O
score	O
for	O
complicated	O
patients	O
(0.60	O
vs	O
0.85).	O
Colonic	B-Therapeutic
anastomosis	I-Therapeutic
leakage	B-Pathologic
had	O
the	O
highest	O
fractional	O
complication	O
burden	O
in	O
both	O
groups	O
.	O
In	O
spite	O
of	O
comparable	O
long-term	O
overall	O
survival,	O
the	O
TLA	B-Diagnostic
group	O
had	O
better	O
recurrence-free	B-Finding
survival	I-Finding
.	O
TLA	B-Diagnostic
for	O
combined	O
resections	O
is	O
feasible,	O
and	O
its	O
indications	O
can	O
be	O
	
==DOCSTART==	
widened	O
to	O
encompass	O
a	O
larger	O
population	O
of	O
patients	O
,	O
provided	O
its	O
benefits	O
in	O
terms	O
of	O
reduced	O
overall	O
risk	O
and	O
severity	O
of	O
complications,	O
rapid	O
functional	B-Sign
recovery	I-Sign
and	O
favorable	O
long-term	O
outcomes	O
.	O
	
==DOCSTART==	
Application	O
of	O
an	O
Analytical	O
Solution	O
as	O
a	O
Screening	O
Tool	O
for	O
Sea	O
Water	O
Intrusion	O
Sea	O
water	O
intrusion	O
into	O
aquifers	O
is	O
problematic	B-Finding
in	O
many	O
coastal	O
areas	O
.	O
The	O
physics	O
and	O
chemistry	O
of	O
this	O
issue	O
are	O
complex	O
,	O
and	O
sea	O
water	O
intrusion	O
remains	O
challenging	O
to	O
quantify	O
.	O
Simple	O
assessment	O
tools	O
like	O
analytical	O
models	O
offer	O
advantages	O
of	O
rapid	O
application	O
,	O
but	O
their	O
applicability	O
to	O
field	O
situations	O
is	O
unclear.	O
This	O
study	O
examines	O
the	O
reliability	O
of	O
a	O
popular	O
sharp-interface	O
analytical	O
approach	O
for	O
estimating	O
the	O
extent	O
of	O
sea	O
water	O
in	O
a	O
homogeneous	O
coastal	O
aquifer	O
subjected	O
to	O
pumping	O
and	O
regional	O
flow	O
effects	O
and	O
under	O
steady-state	O
conditions	O
.	O
The	O
analytical	O
model	O
is	O
tested	O
against	O
observations	O
from	O
Canada	O
,	O
the	O
United	O
States	O
,	O
and	O
Australia	O
to	O
assess	O
its	O
utility	O
as	O
an	O
initial	O
approximation	B-Therapeutic
of	O
sea	O
water	O
extent	O
for	O
the	O
purposes	O
of	O
rapid	O
groundwater	O
management	O
decision	B-Mental
making	I-Mental
.	O
The	O
occurrence	O
of	O
sea	O
water	O
intrusion	O
resulting	O
in	O
increased	O
salinity	O
at	O
pumping	O
wells	O
was	O
correctly	O
predicted	O
in	O
approximately	O
60%	O
of	O
cases	O
.	O
Application	O
of	O
a	O
correction	O
to	O
account	O
for	O
dispersion	O
did	O
not	O
markedly	O
improve	B-Finding
the	O
results	O
.	O
Failure	O
of	O
the	O
analytical	O
model	O
to	O
provide	O
correct	O
predictions	O
can	O
be	O
attributed	O
to	O
mismatches	O
between	O
its	O
simplifying	O
assumptions	O
and	O
more	O
complex	O
field	O
settings.	O
The	O
best	O
results	O
occurred	O
where	O
the	O
toe	O
of	O
the	O
salt	B-Inorganic
water	I-Inorganic
wedge	O
is	O
expected	O
to	O
be	O
the	O
closest	O
to	O
the	O
coast	O
under	O
predevelopment	O
conditions	O
.	O
Predictions	O
were	O
the	O
poorest	O
for	O
aquifers	O
where	O
the	O
salt	B-Inorganic
water	I-Inorganic
wedge	O
was	O
expected	O
to	O
extend	O
further	O
inland	O
under	O
predevelopment	O
conditions	O
and	O
was	O
therefore	O
more	O
dispersive	O
prior	O
to	O
pumping	O
	
==DOCSTART==	
.	O
Sharp-interface	O
solutions	O
remain	O
useful	O
tools	O
to	O
screen	O
for	O
the	O
vulnerability	B-Finding
of	O
coastal	O
aquifers	O
to	O
sea	O
water	O
intrusion	O
,	O
although	O
the	O
significant	O
sources	O
of	O
uncertainty	O
identified	O
in	O
this	O
study	O
require	O
careful	O
consideration	O
to	O
avoid	O
misinterpreting	O
sharp-interface	O
results	O
.	O
	
==DOCSTART==	
Patient	O
-	O
Physician	O
Discordance	O
in	O
Global	O
Assessment	O
in	O
Rheumatoid	B-Disease
Arthritis	I-Disease
:	O
A	O
Systematic	O
Literature	O
Review	O
With	O
Meta-Analysis	O
The	O
integration	O
of	O
the	O
patient	O
in	O
therapeutic	O
decision-making	B-Mental
is	O
important	O
in	O
the	O
management	O
of	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
),	O
but	O
the	O
patient	O
opinion	B-Mental
regarding	O
disease	B-Disease
status	O
may	O
differ	O
from	O
the	O
physician's	O
opinion	B-Mental
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
in	O
the	O
published	O
literature	O
the	O
frequency	O
and	O
drivers	O
of	O
patient	O
-	O
physician	O
discordance	O
in	O
global	O
assessment	O
in	O
RA	B-Disease
.	O
A	O
systematic	O
literature	O
review	O
of	O
all	O
articles	O
published	O
up	O
to	O
January	O
2015	O
in	O
Medline	O
or	O
Embase	O
,	O
reporting	O
discordance	O
in	O
RA	B-Disease
,	O
was	O
conducted	O
by	O
2	O
investigators	O
.	O
Discordance	O
was	O
defined	O
based	O
on	O
the	O
absolute	O
difference	O
of	O
patient	O
global	O
(	O
PGA	O
)	O
and	O
physician	O
global	O
assessments	O
(	O
PhGA	O
)	O
on	O
0-10-cm	O
scales.	O
The	O
frequency	O
of	O
discordance	O
and	O
its	O
predictors	B-Finding
were	O
collected	O
in	O
each	O
study	O
.	O
Frequencies	O
of	O
discordance	O
were	O
pooled	O
by	O
meta-analysis	O
using	O
random	O
effect	O
.	O
In	O
all,	O
12	O
studies	O
were	O
selected	O
(i.e.,	O
11,879	O
patients	O
):	O
weighted	O
mean	O
±	O
SD	O
age	O
was	O
55.1	O
±	O
13.9	O
years	O
,	O
weighted	O
mean	O
±	O
SD	O
disease	O
duration	O
was	O
10.4	O
±	O
9.3	O
years	O
,	O
and	O
80.7%	O
were	O
women	O
.	O
The	O
value	O
of	O
the	O
difference	O
|	O
PGA	O
-	O
PhGA	O
|	O
defining	O
discordance	O
varied	O
between	O
≥0.5	O
cm	O
(n	O
=	O
2	O
studies)	O
to	O
≥3	O
cm	O
(n	O
=	O
5	O
studies);	O
the	O
weighted	O
mean	O
value	O
was	O
2.7	O
cm.	O
The	O
pooled	O
percentage	O
of	O
patients	O
with	O
discordance	O
was	O
43%	O
(95%	O
confidence	O
interval	O
36%-51%;	O
range	O
25%-76%).	O
PGA	O
was	O
usually	O
higher	O
than	O
PhGA	O
.	O
The	O
drivers	O
of	O
	
==DOCSTART==	
PGA	O
were	O
pain	B-Sign
and	O
functional	O
incapacity	O
,	O
whereas	O
drivers	O
of	O
PhGA	O
were	O
joint	O
counts	O
and	O
acute-phase	O
reactants.	O
Discordance	O
in	O
global	O
assessment	O
was	O
most	O
frequently	O
defined	O
as	O
a	O
difference	O
of	O
3	O
points	O
or	O
more;	O
even	O
with	O
such	O
a	O
stringent	O
definition,	O
up	O
to	O
half	O
the	O
patients	O
were	O
found	O
to	O
be	O
discordant	O
.	O
The	O
long-term	O
consequences	O
of	O
this	O
discordance	O
remain	O
to	O
be	O
determined.	O
	
==DOCSTART==	
Nosocomial	B-Disease
pneumonia	I-Disease
caused	O
by	O
methicillin-resistant	B-Bacterium
Staphylococcus	I-Bacterium
aureus	I-Bacterium
treated	B-Therapeutic
with	I-Therapeutic
linezolid	O
or	O
vancomycin:	O
A	O
secondary	O
economic	O
analysis	O
of	O
resource	O
use	O
from	O
a	O
Spanish	O
perspective	O
Adopting	O
a	O
unique	O
Spanish	O
perspective,	O
this	O
study	O
aims	O
to	O
assess	O
healthcare	O
resource	O
utilization	O
(	O
HCRU	O
)	O
and	O
the	O
costs	O
of	O
treating	O
nosocomial	B-Disease
pneumonia	I-Disease
(	O
NP	B-Disease
)	O
produced	O
by	O
methicillin-resistant	B-Bacterium
Staphylococcus	I-Bacterium
aureus	I-Bacterium
(	O
MRSA	B-Bacterium
)	O
in	O
hospitalized	B-Finding
adults	I-Finding
using	O
linezolid	O
or	O
vancomycin.	O
An	O
evaluation	O
is	O
also	O
made	O
of	O
the	O
renal	B-Disease
failure	I-Disease
rate	O
and	O
related	O
economic	O
outcomes	O
between	O
study	O
groups.	O
An	O
economic	O
post	O
hoc	O
evaluation	O
of	O
a	O
randomized	O
,	O
double-blind	O
,	O
multicenter	O
phase	O
4	O
study	O
was	O
carried	O
out.	O
Nosocomial	B-Disease
pneumonia	I-Disease
due	O
to	O
MRSA	B-Bacterium
in	O
hospitalized	B-Finding
adults	I-Finding
.	O
The	O
modified	O
intent	O
to	O
treat	O
(	O
mITT	O
)	O
population	O
comprised	O
224	O
linezolid	O
-	O
and	O
224	O
vancomycin	O
-	O
treated	B-Therapeutic
patients	O
.	O
Costs	O
and	O
HCRU	O
were	O
evaluated	O
between	O
patients	O
administered	O
either	O
linezolid	O
or	O
vancomycin,	O
and	O
between	O
patients	O
who	O
developed	O
renal	B-Disease
failure	I-Disease
and	O
those	O
who	O
did	O
not.	O
Analysis	O
of	O
HCRU	O
outcomes	O
and	O
costs	O
.	O
Total	O
costs	O
were	O
similar	O
between	O
the	O
linezolid	O
-	O
(€17,782±€9,615)	O
and	O
vancomycin	O
-	O
treated	B-Therapeutic
patients	O
(€17,423±€9,460)	O
(P=.69).	O
The	O
renal	B-Disease
failure	I-Disease
rate	O
was	O
significantly	O
lower	O
in	O
the	O
linezolid	O
-	O
treated	B-Therapeutic
patients	O
(4%	O
vs.	O
15%;	O
P<.001).	O
The	O
total	O
costs	O
tended	O
to	O
be	O
higher	O
in	O
patients	O
who	O
developed	O
renal	B-Disease
failure	I-Disease
(€19,626±€10,840	O
vs.	O
€17,388±€9,369;	O
P=.14).	O
Among	O
the	O
patients	O
who	O
developed	O
renal	B-Disease
failure	I-Disease
,	O
HCRU	O
(	O
days	O
on	O
mechanical	B-Therapeutic
ventilation	I-Therapeutic
:	O
13.2±10.7	O
vs.	O
7.6±3.6	O
days	O
;	O
P=.21;	O
ICU	O
stay	O
:	O
14.4±10.5	O
vs.	O
9.9±6.6	O
days	O
;	O
P=.30;	O
hospital	O
stay	O
:	O
19.5±9.5	O
vs.	O
16.1±11.0	O
days	O
;	O
P=.26)	O
and	O
cost	O
	
==DOCSTART==	
(€17,219±€8,792	O
vs.	O
€20,263±€11,350;	O
P=.51)	O
tended	O
to	O
be	O
lower	O
in	O
the	O
linezolid	O
-	O
vs.	O
vancomycin	O
-	O
treated	B-Therapeutic
patients	O
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
costs	O
per	O
patient	O
-	O
day	O
between	O
cohorts	O
after	O
correcting	O
for	O
mortality	O
(€1000	O
vs.	O
€1,010;	O
P=.98).	O
From	O
a	O
Spanish	O
perspective,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
total	O
costs	O
between	O
the	O
linezolid	O
and	O
vancomycin	O
pneumonia	B-Disease
cohorts	O
.	O
The	O
drug	O
cost	O
corresponding	O
to	O
linezolid	O
was	O
partially	O
offset	O
by	O
fewer	O
renal	B-Disease
failure	I-Disease
adverse	B-Pathologic
events	I-Pathologic
.	O
	
==DOCSTART==	
The	O
Role	O
of	O
TRAF4	O
and	O
B3GAT1	O
Gene	B-Genetic
Expression	I-Genetic
in	O
the	O
Food	B-Pathologic
Hypersensitivity	I-Pathologic
and	O
Insect	B-Pathologic
Venom	I-Pathologic
Allergy	I-Pathologic
in	O
Mastocytosis	B-Disease
Mastocytosis	B-Disease
is	O
an	O
uncommon	O
disease	B-Disease
classified	O
as	O
a	O
myeloproliferative	B-Neoplastic
neoplasm	I-Neoplastic
,	O
however,	O
its	O
symptoms	B-Sign
are	O
broad	O
and	O
place	O
patients	O
at	O
crossroads	O
between	O
dermatology	O
,	O
hematology	O
and	O
allergology.	O
Patients	O
with	O
mastocytosis	B-Disease
often	O
suffer	O
from	O
symptoms	B-Sign
resulting	O
from	O
the	O
activation	O
and	O
release	O
of	O
mediators	O
from	O
the	O
mast	B-Cell
cells	I-Cell
,	O
such	O
as	O
generalized	O
itching	B-Sign
,	O
redness	B-Disease
,	O
headache	B-Sign
,	O
abdominal	B-Sign
cramps	I-Sign
,	O
diarrhea	B-Sign
,	O
bone	B-Sign
pain	I-Sign
or	O
arthritis	B-Disease
,	O
hypotension	B-Finding
and	O
shock	B-Pathologic
.	O
The	O
possible	O
severe,	O
fatal	O
or	O
near	O
fatal	O
reactions	O
caused	O
by	O
food	B-Pathologic
hypersensitivity	I-Pathologic
are	O
reasons	O
for	O
the	O
research	O
focused	O
on	O
marker	O
identification.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyse	O
the	O
gene	B-Genetic
expression	I-Genetic
differences	O
in	O
mastocytosis	B-Disease
patients	O
with	O
and	O
without	O
food	B-Pathologic
and	O
drug	B-Pathologic
hypersensitivity	I-Pathologic
and	O
insect	B-Pathologic
venom	I-Pathologic
allergy	I-Pathologic
(	O
IVA	B-Pathologic
).	O
A	O
total	O
of	O
57	O
Caucasian	O
patients	O
with	O
mastocytosis	B-Disease
were	O
studied	O
[median	O
age	O
41.8;	O
range	O
18-77	O
years	O
;	O
15	O
(26.3	O
%)	O
males	O
and	O
42	O
(73.7	O
%)	O
females	O
].	O
Quantitative	B-Molecular
RT-PCRs	I-Molecular
of	O
11	O
genes	O
plus	O
ribosomal	O
18S	O
RNA	O
were	O
run.	O
Symptoms	B-Sign
of	O
food	B-Pathologic
hypersensitivity	I-Pathologic
were	O
found	O
in	O
12	O
patients	O
(21	O
%),	O
including	O
3	O
patients	O
(13	O
%)	O
with	O
cutaneous	B-Neoplastic
mastocytosis	I-Neoplastic
(	O
CM	B-Neoplastic
),	O
and	O
9	O
(28	O
%)	O
with	O
indolent	B-Disease
systemic	I-Disease
mastocytosis	I-Disease
(	O
ISM	B-Disease
).	O
IVA	B-Pathologic
was	O
confirmed	O
in	O
13	O
patients	O
(22.8	O
%)	O
including	O
6	O
patients	O
(10.5	O
%)	O
with	O
CM	B-Neoplastic
,	O
and	O
7	O
patients	O
(12.3	O
%)	O
with	O
ISM	B-Disease
.	O
Drug	B-Pathologic
hypersensitivity	I-Pathologic
was	O
diagnosed	B-Finding
in	O
10	O
patients	O
(17.5	O
%).	O
Significant	O
differences	O
in	O
the	O
gene	B-Genetic
expression	I-Genetic
were	O
found	O
	
==DOCSTART==	
for	O
TRAF4	O
(p	O
=	O
0.008)	O
in	O
the	O
comparison	O
of	O
the	O
mastocytosis	B-Disease
patients	O
with	O
and	O
without	O
concomitant	O
food	B-Pathologic
hypersensitivity	I-Pathologic
.	O
Furthermore	O
significant	O
differences	O
were	O
found	O
in	O
gene	B-Genetic
expression	I-Genetic
for	O
B3GAT1	O
(p	O
=	O
0.003)	O
in	O
patients	O
with	O
IVA	B-Pathologic
compared	O
to	O
patients	O
without	O
insect	B-Injury
sting	I-Injury
anaphylaxis	B-Pathologic
in	O
the	O
medical	O
history.	O
The	O
expression	B-Genetic
of	O
studied	O
genes	O
did	O
not	O
differ	O
according	O
to	O
the	O
presence	O
of	O
drug	B-Pathologic
hypersensitivity	I-Pathologic
.	O
The	O
TRAF4	O
expression	B-Genetic
was	O
higher	O
in	O
mastocytosis	B-Disease
patients	O
with	O
food	B-Pathologic
hypersensitivity	I-Pathologic
in	O
their	O
medical	B-Finding
history	I-Finding
,	O
the	O
B3GAT1	O
expression	B-Genetic
was	O
lower	O
in	O
mastocytosis	B-Disease
patients	O
with	O
IVA	B-Pathologic
in	O
history.	O
	
==DOCSTART==	
Generalized	B-Sign
Weakness	I-Sign
in	O
a	O
Transplant	B-Finding
Patient	O
:	O
A	O
Case	O
Presentation	O
Generalized	B-Sign
weakness	I-Sign
in	O
transplant	B-Finding
patients	O
is	O
a	O
major	O
complaint	O
in	O
tertiary	O
rehabilitation	O
hospitals.	O
The	O
diagnosis	B-Finding
and	O
management	B-Therapeutic
of	O
generalized	B-Sign
weakness	I-Sign
in	O
this	O
population	O
pose	O
challenges	O
for	O
physicians	O
.	O
We	O
present	O
the	O
case	O
of	O
a	O
transplant	B-Finding
patient	O
with	O
generalized	B-Sign
weakness	I-Sign
who	O
was	O
eventually	O
diagnosed	B-Finding
with	O
calciphylaxis	B-Disease
using	O
a	O
multidisciplinary	B-Diagnostic
diagnostic	I-Diagnostic
approach	I-Diagnostic
of	O
electrodiagnostics	B-Diagnostic
,	O
vascular	B-Body
study	B-Diagnostic
,	O
and	O
skin	B-Diagnostic
biopsy	I-Diagnostic
.	O
Calciphylaxis	B-Disease
is	O
a	O
rare	O
cutaneous	B-Disease
disorder	I-Disease
that	O
mimics	O
other	O
collagen	B-Disease
vascular	I-Disease
diseases	I-Disease
in	O
its	O
presentation	O
and	O
fulminant	O
course.	O
Physiatrists	O
should	O
be	O
cognizant	O
of	O
calciphylaxis	B-Disease
,	O
as	O
it	O
signals	O
a	O
poor	B-Finding
prognosis	I-Finding
if	O
not	O
correctly	O
diagnosed	O
and	O
treated	O
in	O
a	O
timely	O
manner	O
,	O
with	O
high	O
incidence	O
of	O
sepsis	B-Disease
,	O
wound	B-Sign
pain	I-Sign
,	O
and	O
disability	B-Finding
.	O
V.	O
	
==DOCSTART==	
Use	O
of	O
ecoacoustics	O
to	O
determine	O
biodiversity	O
patterns	O
across	O
ecological	O
gradients	O
The	O
variety	O
of	O
local	O
animal	O
sounds	O
characterizes	O
a	O
landscape	O
.	O
We	O
used	O
ecoacoustics	O
to	O
noninvasively	O
assess	O
the	O
species	O
richness	O
of	O
various	O
biotopes	O
typical	O
of	O
an	O
ecofriendly	O
forest	O
plantation	O
with	O
diverse	O
ecological	O
gradients	O
and	O
both	O
nonnative	B-Finding
and	O
indigenous	O
vegetation	O
.	O
The	O
reference	O
area	O
was	O
an	O
adjacent	O
large	O
World	O
Heritage	O
Site	O
protected	O
area	O
(	O
PA	O
).	O
All	O
sites	O
were	O
in	O
a	O
global	O
biodiversity	O
hotspot	O
.	O
Our	O
results	O
showed	O
how	O
taxa	O
segregated	O
into	O
various	O
biotopes	O
.	O
We	O
identified	O
65	O
singing	O
species	O
,	O
including	O
birds	O
,	O
frogs	O
,	O
crickets	B-Eukaryote
,	O
and	O
katydids	B-Eukaryote
.	O
Large	O
,	O
natural	O
,	O
protected	O
grassland	O
sites	O
in	O
the	O
PA	O
had	O
the	O
highest	O
mean	O
acoustic	O
diversity	O
(14.1	O
species	O
/	O
site	O
).	O
Areas	O
covered	O
in	O
nonnative	O
timber	O
or	O
grass	O
species	O
were	O
devoid	O
of	O
acoustic	O
species	O
.	O
Sites	O
grazed	O
by	O
native	O
and	O
domestic	O
megaherbivores	O
were	O
fairly	O
rich	O
(5.1)	O
in	O
acoustic	O
species	O
but	O
none	O
were	O
unique	O
to	O
this	O
habitat	O
type	O
,	O
where	O
acoustic	O
diversity	O
was	O
greater	O
than	O
in	O
intensively	O
managed	O
grassland	O
sites	O
(0.04).	O
Natural	O
vegetation	O
patches	O
inside	O
the	O
plantation	O
mosaic	O
supported	O
high	O
mean	O
acoustic	O
diversity	O
(	O
indigenous	O
forests	O
7.6,	O
grasslands	O
8.0,	O
wetlands	O
9.1),	O
which	O
increased	O
as	O
plant	O
heterogeneity	O
and	O
patch	O
size	O
increased	O
.	O
Indigenous	O
forest	O
patches	O
within	O
the	O
plantation	O
mosaic	O
contained	O
a	O
highly	O
characteristic	O
acoustic	O
species	O
assemblage	O
,	O
emphasizing	O
their	O
complementary	O
contribution	O
to	O
local	O
biodiversity	O
.	O
Overall,	O
acoustic	O
signals	O
determined	O
spatial	O
biodiversity	O
patterns	O
and	O
can	O
be	O
a	O
useful	O
tool	O
for	O
guiding	O
conservation	O
.	O
	
==DOCSTART==	
A	O
Randomized	O
Controlled	O
Noninferiority	O
Trial	O
of	O
Single	O
Dose	O
of	O
Oral	B-Clinical
Dexamethasone	I-Clinical
Versus	O
5	O
Days	O
of	O
Oral	B-Clinical
Prednisone	I-Clinical
in	O
Acute	O
Adult	O
Asthma	B-Disease
Oral	B-Clinical
dexamethasone	I-Clinical
demonstrates	O
bioavailability	O
similar	O
to	O
that	O
of	O
oral	B-Clinical
prednisone	I-Clinical
but	O
has	O
a	O
longer	O
half-life	O
.	O
We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	B-Clinical
dexamethasone	I-Clinical
plus	O
4	O
days	O
of	O
placebo	B-Biomedical
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	B-Clinical
prednisone	I-Clinical
in	O
treatment	O
of	O
adults	O
with	O
mild	B-Finding
to	O
moderate	B-Finding
asthma	B-Finding
exacerbations	I-Finding
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	B-Finding
treatment	I-Finding
for	O
persistent	B-Disease
or	O
worsening	O
asthma	B-Disease
within	O
14	O
days	O
.	O
Adult	O
emergency	O
department	O
patients	O
(	O
aged	O
18	O
to	O
55	O
years	O
)	O
were	O
randomized	O
to	O
receive	O
either	O
a	O
single	O
dose	O
of	O
12	O
mg	O
of	O
oral	B-Clinical
dexamethasone	I-Clinical
with	O
4	O
days	O
of	O
placebo	B-Biomedical
or	O
a	O
5-	O
day	O
course	O
of	O
oral	B-Clinical
prednisone	I-Clinical
60	O
mg	O
a	O
day	O
.	O
Outcomes	O
including	O
relapse	O
were	O
assessed	O
by	O
a	O
follow-up	O
telephone	O
interview	O
at	O
2	O
weeks	O
.	O
One	O
hundred	O
seventy-three	O
dexamethasone	O
and	O
203	O
prednisone	O
subjects	O
completed	O
the	O
study	O
regimen	O
and	O
telephone	O
follow-up	O
.	O
The	O
dexamethasone	O
group	O
by	O
a	O
small	O
margin	O
surpassed	O
the	O
preset	O
8%	O
difference	O
between	O
groups	O
for	O
noninferiority	O
in	O
relapse	O
rates	O
within	O
14	O
days	O
(12.1%	O
versus	O
9.8%;	O
difference	O
2.3%;	O
95%	O
confidence	O
interval	O
-4.1%	O
to	O
8.6%).	O
Subjects	O
in	O
the	O
2	O
groups	O
had	O
similar	O
rates	O
of	O
hospitalization	O
for	O
their	O
relapse	O
visit	O
(dexamethasone	O
3.4%	O
versus	O
prednisone	O
2.9%;	O
difference	O
0.5%;	O
95%	O
confidence	O
interval	O
-4.1%	O
to	O
3.1%).	O
Adverse	O
effect	O
rates	O
were	O
generally	O
the	O
same	O
in	O
the	O
2	O
groups.	O
A	O
single	O
dose	O
of	O
oral	B-Clinical
dexamethasone	I-Clinical
did	O
not	O
demonstrate	O
noninferiority	O
to	O
prednisone	O
for	O
5	O
days	O
	
==DOCSTART==	
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	O
of	O
adults	O
with	O
mild	B-Finding
to	O
moderate	B-Finding
asthma	B-Finding
exacerbations	I-Finding
.	O
Enhanced	O
compliance	B-Finding
and	O
convenience	O
may	O
support	O
the	O
use	O
of	O
dexamethasone	O
regardless.	O
	
==DOCSTART==	
Relationship	O
between	O
XspI	O
Site	B-Cell
Polymorphisms	I-Cell
of	O
LDL-R	O
Gene	O
and	O
Serum	O
IL-2	O
and	O
IL-10	O
in	O
Patients	O
with	O
Hypercholesterolemia	B-Disease
Relationship	O
has	O
been	O
identified	O
in	O
sporadic	B-Finding
reports	I-Finding
between	O
polymorphisms	B-Genetic
and	O
hypercholesterolemia	B-Disease
.	O
However,	O
the	O
relationship	O
between	O
inflammatory	O
cytokines	O
and	O
polymorphism	B-Genetic
of	O
low-density	O
lipoprotein	O
receptor	O
(LDL-R)	O
gene	O
in	O
hypercholesterolemia	B-Disease
is	O
unclear	B-Finding
.	O
This	O
study	O
aimed	O
to	O
explore	O
the	O
relationship	O
and	O
significance	O
between	O
polymorphisms	B-Genetic
of	O
LDL-R	O
gene	O
and	O
serum	O
Interleukin-2	O
(IL-2),	O
IL-10	O
in	O
patients	O
with	O
hypercholesterolemia	B-Disease
.	O
PCR-RFLP	B-Laboratory
and	O
direct	O
DNA	O
sequencing	O
assay	O
were	O
employed	B-Finding
to	O
determine	O
polymorphism	B-Genetic
of	O
LDL-R	O
gene	O
in	O
900	O
patients	O
with	O
hypercholesterolemia	B-Disease
and	O
400	O
healthy	O
cases	O
.	O
ELISA	B-Laboratory
was	O
applied	O
to	O
assay	O
serum	O
concentration	O
of	O
IL-2	O
and	O
IL-10.	O
Blood	B-Organic
lipid	I-Organic
indexes	O
were	O
tested	O
in	O
all	O
cases	O
.	O
Compared	O
with	O
the	O
healthy	O
controls	O
,	O
level	O
of	O
IL-2	O
increased	O
significantly	O
,	O
while	O
IL-10	O
decreased	O
significantly	O
(P	O
<	O
0.05).	O
Correlation	O
analysis	O
showed	O
that	O
IL-2	O
was	O
positively	B-Finding
correlated	O
with	O
total	B-Organic
cholesterol	I-Organic
(	O
TC	B-Organic
),	O
LDL-c,	O
and	O
genotype	O
(r	O
=	O
0.542,	O
0.410,	O
0.598,	O
P	O
<	O
0.05)	O
and	O
negatively	B-Finding
correlated	O
with	O
HDL-c	O
(r	O
=	O
-0.352,	O
P	O
<	O
0.05).	O
Negative	B-Finding
relationship	O
also	O
was	O
found	O
between	O
TC	B-Organic
,	O
LDL-c,	O
genotype	O
,	O
and	O
IL-10	O
(r	O
=	O
-0.452,	O
-0.390,	O
-0.613,	O
P	O
<	O
0.05),	O
and	O
positive	B-Finding
correlation	O
between	O
HDL-c	O
and	O
IL-10	O
(r	O
=	O
0.398,	O
P	O
<	O
0.05).	O
Multiple	O
linear	O
regression	O
showed	O
that	O
genotypes	O
and	O
TC	B-Organic
were	O
independent	O
factors	O
affecting	O
the	O
levels	B-Laboratory
of	I-Laboratory
IL-2	I-Laboratory
and	O
IL-10	B-Laboratory
(P	O
<	O
0.05).	O
IL-2	O
and	O
IL-10	O
were	O
related	O
to	O
gene	B-Genetic
polymorphisms	I-Genetic
of	O
LDL-R	O
,	O
which	O
might	O
be	O
involved	O
in	O
the	O
development	O
and	O
progress	O
of	O
hypercholesterolemia	B-Disease
.	O
	
==DOCSTART==	
HERG1	O
potassium	O
channel	O
expression	B-Genetic
in	O
potentially	O
malignant	B-Neoplastic
disorders	I-Neoplastic
of	O
the	O
oral	B-Body
mucosa	I-Body
and	O
prognostic	O
relevance	O
in	O
oral	B-Neoplastic
squamous	I-Neoplastic
cell	I-Neoplastic
carcinoma	I-Neoplastic
HERG1	O
potassium	O
channel	O
plays	O
a	O
critical	O
role	O
in	O
the	O
cell	B-Cell
proliferation	I-Cell
.	O
HERG1	O
protein	O
expression	B-Genetic
was	O
analyzed	O
by	O
immunohistochemistry	B-Diagnostic
(	O
IHC	B-Diagnostic
)	O
in	O
62	O
patients	O
with	O
oral	B-Neoplastic
leukoplakias	I-Neoplastic
and	O
100	O
patients	O
with	O
oral	B-Neoplastic
squamous	I-Neoplastic
cell	I-Neoplastic
carcinomas	I-Neoplastic
(	O
OSCC	B-Neoplastic
).	O
HERG1	O
mRNA	O
levels	O
were	O
assessed	O
by	O
real-time	B-Molecular
reverse	I-Molecular
transcriptase-polymerase	I-Molecular
chain	I-Molecular
reaction	I-Molecular
(	O
RT-PCR	B-Molecular
)	O
in	O
22	O
patients	O
with	O
primary	O
head	B-Neoplastic
and	I-Neoplastic
neck	I-Neoplastic
squamous	I-Neoplastic
cell	I-Neoplastic
carcinoma	I-Neoplastic
(	O
HNSCC	B-Neoplastic
).	O
Statistically	O
significant	O
associations	O
were	O
found	O
between	O
HERG1	O
expression	B-Genetic
and	O
tobacco	O
consumption	O
,	O
disease	B-Diagnostic
stage	I-Diagnostic
,	O
tumor	B-Neoplastic
differentiation	B-Cell
,	O
tumor	B-Neoplastic
recurrence	I-Neoplastic
,	O
and	O
reduced	O
survival	O
.	O
There	O
was	O
no	O
association	O
between	O
HERG1	O
expression	B-Genetic
and	O
the	O
risk	O
of	O
progression	B-Neoplastic
from	O
oral	B-Neoplastic
leukoplakia	I-Neoplastic
to	O
OSCC	B-Neoplastic
.	O
In	O
addition,	O
a	O
high	O
proportion	O
of	O
tumors	B-Neoplastic
(80%)	O
showed	O
increased	O
HERG1	O
mRNA	O
levels	O
compared	O
to	O
normal	B-Tissue
mucosa	I-Tissue
from	O
nononcologic	O
patients	O
.	O
Aberrant	O
HERG1	O
expression	B-Genetic
increases	O
as	O
oral	O
tumorigenesis	B-Neoplastic
progresses	I-Neoplastic
from	O
oral	B-Pathologic
hyperplasia	I-Pathologic
to	O
OSCC	B-Neoplastic
.	O
Increased	O
HERG1	O
mRNA	O
levels	O
were	O
also	O
frequently	O
detected	B-Finding
in	O
OSCC	B-Neoplastic
and	O
other	O
HNSCC	B-Neoplastic
subsites	O
.	O
HERG1	O
expression	B-Genetic
emerges	O
as	O
a	O
clinically	O
relevant	O
feature	O
during	O
tumor	B-Neoplastic
progression	I-Neoplastic
and	O
a	O
potential	O
poor	O
prognostic	O
biomarker	O
for	O
OSCC	B-Neoplastic
.	O
©	O
2016	O
Wiley	O
Periodicals,	O
Inc.	O
Head	O
Neck	O
38:	O
1708-1716,	O
2016.	O
	
==DOCSTART==	
Malignancy	B-Neoplastic
is	O
associated	O
with	O
microcalcification	B-Pathologic
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	B-Diagnostic
,	O
but	O
not	O
with	O
Hashimoto's	B-Disease
thyroiditis	I-Disease
in	O
histopathology	B-Laboratory
in	O
patients	O
with	O
thyroid	B-Neoplastic
nodules	I-Neoplastic
evaluated	O
as	O
Bethesda	B-Neoplastic
Category	I-Neoplastic
III	I-Neoplastic
(	O
AUS	B-Cell
/	O
FLUS	B-Finding
)	O
in	O
cytology	B-Laboratory
The	O
predictors	O
of	O
malignancy	B-Neoplastic
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	B-Neoplastic
with	O
atypia	B-Cell
of	I-Cell
undetermined	I-Cell
significance	I-Cell
/	O
follicular	B-Finding
lesion	I-Finding
of	I-Finding
undetermined	I-Finding
significance	I-Finding
(	O
AUS	B-Cell
/	O
FLUS	B-Finding
).	O
Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
predictors	O
of	O
malignancy	B-Neoplastic
in	O
these	O
patients	O
.	O
A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	B-Neoplastic
Bethesda	I-Neoplastic
Category	I-Neoplastic
III	I-Neoplastic
(	O
AUS	B-Cell
/	O
FLUS	B-Finding
)	O
thyroid	B-Neoplastic
nodules	I-Neoplastic
were	O
included	O
in	O
this	O
retrospective	O
study	O
.	O
We	O
divided	O
the	O
nodules	B-Neoplastic
into	O
two	O
subgroups	O
according	O
to	O
the	O
histopathology	B-Laboratory
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	B-Finding
findings	I-Finding
.	O
In	O
overall,	O
427	O
patients	O
with	O
449	O
AUS	B-Cell
/	O
FLUS	B-Finding
nodules	B-Neoplastic
who	O
had	O
undergone	O
surgery	B-Therapeutic
,	O
the	O
rate	O
of	O
malignancy	B-Neoplastic
was	O
23.4	O
%	O
(105/449).	O
When	O
evaluated	O
separately,	O
the	O
rate	O
of	O
malignancy	B-Neoplastic
was	O
25.8	O
%	O
in	O
nodules	B-Neoplastic
with	O
AUS	B-Cell
(82/318)	O
and	O
17.6	O
%	O
in	O
nodules	B-Neoplastic
with	O
FLUS	B-Finding
(23/131)	O
(p	O
=	O
0.061).	O
The	O
vast	O
majority	O
of	O
malignant	O
specimens	O
in	O
histopathology	B-Laboratory
consisted	O
of	O
papillary	B-Neoplastic
thyroid	I-Neoplastic
carcinoma	I-Neoplastic
(	O
PTC	B-Neoplastic
)	O
(n	O
=	O
91,	O
86.7	O
%).	O
Preoperative	O
ultrasonographic	O
features	O
of	O
105	O
malignant	B-Neoplastic
nodules	I-Neoplastic
in	O
histopathology	B-Laboratory
were	O
compared	O
with	O
the	O
344	O
benign	B-Neoplastic
nodules	I-Neoplastic
in	O
histopathology	B-Laboratory
.	O
Anteroposterior/Transverse	O
(AP/T)	O
ratio	O
was	O
significantly	O
higher	O
in	O
malignant	O
group	O
compared	O
to	O
benign	O
group	O
(p	O
=	O
0.013).	O
In	O
multiple	O
logistic	O
analysis	O
,	O
we	O
found	O
that	O
	
==DOCSTART==	
higher	O
AP/T	O
ratio	O
and	O
microcalcification	B-Pathologic
were	O
independently	O
associated	O
with	O
malignancy	B-Neoplastic
(p	O
<	O
0.05).	O
The	O
malignancy	B-Neoplastic
-associated	O
cut-off	O
value	O
of	O
AP/T	O
ratio	O
at	O
maximum	O
sensitivity	O
and	O
specificity	O
was	O
≥0.81.	O
We	O
did	O
not	O
find	O
any	O
correlation	O
between	O
malignancy	B-Neoplastic
and	O
Hashimoto's	B-Disease
thyroiditis	I-Disease
in	O
histopathology	B-Laboratory
in	O
multivariate	O
analysis	O
(p	O
>	O
0.05).	O
In	O
Bethesda	B-Neoplastic
Category	I-Neoplastic
III	I-Neoplastic
nodules	I-Neoplastic
with	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	B-Pathologic
,	O
surgery	B-Therapeutic
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine-needle	B-Diagnostic
aspiration	I-Diagnostic
biopsy	I-Diagnostic
or	O
observation	O
.	O
	
==DOCSTART==	
Low	O
serum	B-Body
vitamin	O
D	O
is	O
associated	O
with	O
higher	O
cortical	B-Body
porosity	O
in	O
elderly	O
men	O
Bone	B-Disease
loss	I-Disease
at	O
peripheral	O
sites	B-Body
in	O
the	O
elderly	O
is	O
mainly	O
cortical	B-Body
and	O
involves	O
increased	O
cortical	B-Body
porosity	O
.	O
However,	O
an	O
association	O
between	O
bone	B-Disease
loss	I-Disease
at	O
these	O
sites	B-Body
and	O
25-hydroxyvitamin	O
D	O
has	O
not	O
been	O
reported.	O
To	O
investigate	O
the	O
association	O
between	O
serum	B-Body
levels	B-Laboratory
of	I-Laboratory
25-hydroxyvitamin	I-Laboratory
D	I-Laboratory
,	O
bone	B-Body
microstructure	I-Body
and	O
areal	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
elderly	O
men	O
.	O
A	O
population	O
-based	O
cohort	O
of	O
444	O
elderly	O
men	O
(mean	O
±	O
SD	O
age	O
80.2	O
±	O
3.5	O
years	O
)	O
was	O
investigated	O
.	O
Bone	B-Body
microstructure	I-Body
was	O
measured	O
by	O
high-resolution	B-Diagnostic
peripheral	I-Diagnostic
quantitative	I-Diagnostic
computed	I-Diagnostic
tomography	I-Diagnostic
,	O
areal	O
BMD	O
by	O
dual-energy	B-Diagnostic
X-ray	I-Diagnostic
absorptiometry	I-Diagnostic
and	O
serum	B-Body
25-hydroxyvitamin	B-Laboratory
D	I-Laboratory
and	O
parathyroid	B-Laboratory
hormone	I-Laboratory
levels	I-Laboratory
by	O
immunoassay	B-Laboratory
.	O
Mean	O
cortical	B-Body
porosity	O
at	O
the	O
distal	B-Body
tibia	I-Body
was	O
14.7%	O
higher	O
(12.5	O
±	O
4.3%	O
vs.	O
10.9	O
±	O
4.1%,	O
P	O
<	O
0.05)	O
whilst	O
cortical	B-Body
volumetric	O
BMD	O
,	O
area	O
,	O
trabecular	B-Tissue
bone	I-Tissue
volume	O
fraction	O
and	O
femoral	B-Body
neck	I-Body
areal	O
BMD	O
were	O
lower	O
in	O
men	O
in	O
the	O
lowest	O
quartile	O
of	O
vitamin	B-Laboratory
D	I-Laboratory
levels	I-Laboratory
compared	O
to	O
the	O
highest.	O
In	O
men	O
with	O
vitamin	B-Disease
D	I-Disease
deficiency	I-Disease
(<25	O
nmol	O
L(-1))	O
or	O
insufficiency	O
[25-49	O
nmol	O
L(-1),	O
in	O
combination	O
with	O
an	O
elevated	O
serum	B-Body
level	B-Laboratory
of	I-Laboratory
parathyroid	I-Laboratory
hormone	I-Laboratory
(>6.8	O
pmol	O
L(-1))],	O
cortical	B-Body
porosity	O
was	O
17.2%	O
higher	O
than	O
in	O
vitamin	O
D	O
-	O
sufficient	O
men	O
(P	O
<	O
0.01).	O
A	O
linear	O
regression	O
model	O
including	O
age	O
,	O
weight	O
,	O
height	O
,	O
daily	B-Therapeutic
calcium	I-Therapeutic
intake	I-Therapeutic
,	O
physical	O
activity	O
,	O
smoking	O
vitamin	O
D	O
supplementation	B-Pharmacologic
and	O
parathyroid	O
hormone	O
showed	O
that	O
25-hydroxyvitamin	O
D	O
independently	O
predicted	O
cortical	B-Body
porosity	O
(standardized	O
β	O
=	O
-0.110,	O
	
==DOCSTART==	
R(2)	O
=	O
1.1%,	O
P	O
=	O
0.024),	O
area	O
(β	O
=	O
0.123,	O
R(2)	O
=	O
1.4%,	O
P	O
=	O
0.007)	O
and	O
cortical	B-Body
volumetric	O
BMD	O
(β	O
=	O
0.125,	O
R(2)	O
=	O
1.4%,	O
P	O
=	O
0.007)	O
of	O
the	O
tibia	B-Body
as	O
well	O
as	O
areal	O
BMD	O
of	O
the	O
femoral	B-Body
neck	I-Body
(β	O
=	O
0.102,	O
R(2)	O
=	O
0.9%,	O
P	O
=	O
0.04).	O
Serum	B-Body
vitamin	O
D	O
is	O
associated	O
with	O
cortical	B-Body
porosity	O
,	O
area	O
and	O
density	O
,	O
indicating	O
that	O
bone	B-Body
fragility	B-Cell
as	O
a	O
result	O
of	O
low	O
vitamin	O
D	O
could	O
be	O
due	O
to	O
changes	O
in	O
cortical	B-Body
bone	B-Body
microstructure	I-Body
and	O
geometry	O
.	O
	
==DOCSTART==	
Nationwide	O
reduction	O
in	O
the	O
number	O
of	O
corneal	B-Therapeutic
transplantations	I-Therapeutic
for	O
keratoconus	B-Disease
following	O
the	O
implementation	O
of	O
cross-linking	B-Therapeutic
Keratoconus	B-Disease
is	O
characterized	O
by	O
corneal	B-Disease
ectasia	I-Disease
and	O
irregular	B-Disease
astigmatism	I-Disease
,	O
which	O
can	O
lead	O
to	O
diminished	B-Disease
vision	I-Disease
and	O
corneal	B-Finding
scarring	I-Finding
.	O
Approximately	O
10-20%	O
of	O
patients	O
with	O
keratoconus	B-Disease
eventually	O
require	O
a	O
corneal	B-Therapeutic
transplant	I-Therapeutic
.	O
Corneal	B-Therapeutic
cross-linking	I-Therapeutic
(	O
CXL	B-Therapeutic
)	O
is	O
a	O
relatively	O
new	O
treatment	B-Therapeutic
that	O
may	O
help	O
prevent	O
the	O
need	O
for	O
corneal	B-Therapeutic
transplantation	I-Therapeutic
.	O
Here,	O
we	O
investigated	O
whether	O
the	O
introduction	O
of	O
CXL	B-Therapeutic
has	O
reduced	O
the	O
number	O
of	O
corneal	B-Therapeutic
transplants	I-Therapeutic
performed	O
annually	O
.	O
Data	O
regarding	O
the	O
transplantation	B-Therapeutic
procedures	I-Therapeutic
performed	O
in	O
patients	O
under	O
the	O
age	O
of	O
50	O
years	O
were	O
extracted	O
from	O
the	O
Dutch	O
National	O
Organ	O
Transplant	O
Registry	O
.	O
The	O
number	O
of	O
corneal	B-Therapeutic
transplants	I-Therapeutic
performed	O
prior	O
to	O
(i.e.	O
in	O
2005	O
through	O
2007)	O
and	O
following	O
the	O
introduction	O
of	O
CXL	B-Therapeutic
(i.e.	O
in	O
2012	O
through	O
2014)	O
were	O
compared	O
.	O
Furthermore,	O
a	O
trend	O
analysis	O
on	O
annual	O
keratoplasties	B-Therapeutic
over	O
time	O
was	O
performed	O
.	O
Approximately	O
25%	O
fewer	O
corneal	B-Therapeutic
transplants	I-Therapeutic
were	O
performed	O
in	O
the	O
3-	O
year	O
period	O
following	O
the	O
introduction	O
of	O
CXL	B-Therapeutic
compared	O
to	O
the	O
3-	O
year	O
period	O
prior	O
to	O
the	O
introduction	O
of	O
CXL	B-Therapeutic
(201	O
versus	O
269	O
transplants	B-Therapeutic
,	O
respectively;	O
p	O
=	O
0.005).	O
Age	O
,	O
gender	O
and	O
visual	O
acuity	O
were	O
similar	O
between	O
the	O
patient	O
groups	O
in	O
the	O
two	O
time	O
periods	O
.	O
Trend	O
analysis	O
also	O
demonstrated	O
a	O
significant	O
decrease	O
in	O
the	O
amount	O
of	O
corneal	B-Therapeutic
transplants	I-Therapeutic
(p	O
=	O
0.001).	O
Significantly	O
fewer	O
corneal	B-Therapeutic
transplants	I-Therapeutic
were	O
performed	O
for	O
treating	O
keratoconus	B-Disease
following	O
the	O
nationwide	O
introduction	O
of	O
CXL	B-Therapeutic
.	O
This	O
reduction	O
suggests	O
that	O
corneal	B-Therapeutic
cross-linking	I-Therapeutic
can	O
significantly	O
reduce	O
the	O
need	O
for	O
corneal	B-Therapeutic
transplantation	I-Therapeutic
	
==DOCSTART==	
.	O
	
==DOCSTART==	
Rapid	O
Fabrication	O
of	O
a	O
Cell	B-Cell
-	O
Seeded	B-Laboratory
Collagen	B-Amino
Gel	B-Biomedical
-Based	O
Tubular	B-Medical
Construct	I-Medical
that	O
Withstands	O
Arterial	B-Organ
Pressure	I-Organ
:	O
Rapid	O
Fabrication	O
of	O
a	O
Gel	B-Biomedical
-Based	O
Media	O
Equivalent	O
Based	O
on	O
plastically	O
compressed	O
cell	B-Cell
-	O
seeded	B-Laboratory
collagen	B-Amino
gels	B-Biomedical
,	O
we	O
fabricated	O
a	O
small-diameter	O
tubular	B-Medical
construct	I-Medical
that	O
withstands	O
arterial	B-Organ
pressure	I-Organ
without	O
prolonged	O
culture	B-Laboratory
in	O
vitro	O
.	O
Specifically,	O
to	O
mimic	O
the	O
microstructure	O
of	O
vascular	B-Tissue
media	I-Tissue
,	O
the	O
cell	B-Cell
-	O
seeded	B-Laboratory
collagen	B-Amino
gel	B-Biomedical
was	O
uniaxially	O
stretched	O
prior	O
to	O
plastic	O
compression	O
to	O
align	O
collagen	B-Tissue
fibers	I-Tissue
and	O
hence	O
cells	B-Cell
in	O
the	O
gel	B-Biomedical
.	O
The	O
resulting	O
gel	B-Biomedical
sheet	B-Biomedical
was	O
then	O
wrapped	O
around	O
a	O
custom-made	O
multi-layered	B-Medical
braided	I-Medical
tube	I-Medical
to	O
form	O
aligned	O
tubular	B-Medical
constructs	I-Medical
whereas	O
the	O
gel	B-Biomedical
sheet	B-Biomedical
prepared	O
similarly	O
but	O
without	O
uniaxial	O
stretching	O
formed	O
control	O
constructs	B-Medical
.	O
With	O
the	O
braided	B-Medical
tube	I-Medical
,	O
fluid	O
in	O
the	O
gel	B-Biomedical
construct	B-Medical
was	O
further	O
removed	O
by	O
vacuum	B-Medical
suction	I-Medical
aiming	O
to	O
consolidate	O
the	O
concentric	O
layers	O
of	O
the	O
construct	B-Medical
.	O
The	O
construct	B-Medical
was	O
finally	O
treated	O
with	O
transglutaminase.	O
Both	O
SEM	B-Laboratory
and	O
histology	B-Laboratory
confirmed	O
the	O
absence	O
of	O
gaps	O
in	O
the	O
wall	O
of	O
the	O
construct	B-Medical
.	O
Particularly,	O
cells	B-Cell
in	O
the	O
wall	O
of	O
the	O
aligned	O
tubular	B-Medical
construct	I-Medical
were	O
circumferentially	O
aligned.	O
The	O
enzyme	O
-mediated	O
crosslinking	O
increased	O
burst	O
pressure	O
of	O
both	O
the	O
constructs	B-Medical
significantly;	O
the	O
extent	O
of	O
the	O
increase	O
of	O
burst	O
pressure	O
for	O
the	O
aligned	O
tubular	B-Medical
construct	I-Medical
was	O
greater	O
than	O
that	O
for	O
the	O
control	O
counterpart.	O
Increasing	O
crosslinking	O
left	O
the	O
compliance	O
of	O
the	O
aligned	O
tubular	B-Medical
construct	I-Medical
unchanged	O
but	O
reduced	O
that	O
of	O
the	O
control	O
construct	B-Medical
.	O
Cells	B-Cell
remained	O
viable	O
in	O
transglutaminase	O
-treated	O
plastically	O
compressed	O
gels	B-Biomedical
after	O
6	O
days	O
in	O
culture.	O
This	O
study	O
demonstrated	O
that	O
by	O
combining	O
	
==DOCSTART==	
stretch-induced	O
fiber	B-Tissue
alignment	O
,	O
plastic	O
compression	O
,	O
and	O
enzyme	O
-mediated	O
crosslinking	O
,	O
a	O
cell	B-Cell
-	O
seeded	B-Laboratory
collagen	B-Amino
gel	B-Biomedical
-based	O
tubular	B-Medical
construct	I-Medical
with	O
potential	O
to	O
be	O
used	O
as	O
vascular	B-Tissue
media	I-Tissue
can	O
be	O
made	O
within	O
3	O
days	O
.	O
	
==DOCSTART==	
Impact	O
of	O
cofactor	B-Biologically
-	O
binding	O
loop	O
mutations	B-Genetic
on	O
thermotolerance	B-Physiologic
and	O
activity	B-Molecular
of	O
E.	B-Bacterium
coli	I-Bacterium
transketolase	O
Improvement	O
of	O
thermostability	O
in	O
engineered	O
enzymes	O
can	O
allow	O
biocatalysis	O
on	O
substrates	O
with	O
poor	O
aqueous	O
solubility	O
.	O
Denaturation	B-Molecular
of	O
the	O
cofactor	B-Biologically
-	O
binding	O
loops	O
of	O
Escherichia	B-Bacterium
coli	I-Bacterium
transketolase	O
(TK)	O
was	O
previously	O
linked	O
to	O
the	O
loss	O
of	O
enzyme	B-Molecular
activity	I-Molecular
under	O
conditions	O
of	O
high	O
pH	O
or	O
urea.	O
Incubation	B-Laboratory
at	O
temperatures	O
just	O
below	O
the	O
thermal	O
melting	O
transition	O
,	O
above	O
which	O
the	O
protein	O
aggregates	O
,	O
was	O
also	O
found	O
to	O
anneal	O
the	O
enzyme	O
to	O
give	O
an	O
increased	O
specific	O
activity	B-Molecular
.	O
The	O
potential	O
role	O
of	O
cofactor	B-Biologically
-	O
binding	O
loop	O
instability	B-Finding
in	O
this	O
process	O
remained	O
unclear.	O
In	O
this	O
work,	O
the	O
two	O
cofactor	B-Biologically
-	O
binding	O
loops	O
(	O
residues	O
185-192	O
and	O
382-392	O
)	O
were	O
progressively	O
mutated	O
towards	O
the	O
equivalent	O
sequence	O
from	O
the	O
thermostable	O
Thermus	B-Bacterium
thermophilus	I-Bacterium
TK	O
and	O
variants	O
assessed	O
for	O
their	O
impact	O
on	O
both	O
thermostability	O
and	O
activity	O
.	O
Cofactor-binding	O
loop	O
2	O
variants	O
had	O
detrimental	O
effects	O
on	O
specific	O
activity	O
at	O
elevated	O
temperatures	O
,	O
whereas	O
the	O
H192P	B-Genetic
mutation	I-Genetic
in	O
cofactor-binding	O
loop	O
1	O
resulted	O
in	O
a	O
two-fold	O
improved	O
stability	O
to	O
inactivation	O
at	O
elevated	O
temperatures	O
,	O
and	O
increased	O
the	O
critical	O
onset	O
temperature	O
for	O
aggregation	O
.	O
The	O
specific	O
activity	O
of	O
H192P	B-Genetic
was	O
3-fold	O
and	O
19-fold	O
higher	O
than	O
that	O
for	O
wild-type	O
at	O
60°C	O
and	O
65°C	O
respectively,	O
and	O
also	O
remained	O
2.7-4	O
fold	O
higher	O
after	O
re-cooling	O
from	O
pre-incubations	B-Laboratory
at	O
either	O
55°C	O
or	O
60°C	O
for	O
1h.	O
Interestingly,	O
H192P	B-Genetic
was	O
also	O
2-times	O
more	O
active	O
than	O
wild-type	O
TK	O
at	O
25°C.	O
Optimal	O
activity	O
was	O
achieved	O
at	O
60°C	O
for	O
H192P	B-Genetic
compared	O
to	O
55°C	O
for	O
wild	O
type	O
.	O
These	O
	
==DOCSTART==	
results	O
show	O
that	O
cofactor-binding	O
loop	O
1	O
,	O
plays	O
a	O
pivotal	O
role	O
in	O
partial	O
denaturation	B-Molecular
and	O
aggregation	O
at	O
elevated	O
temperatures	O
.	O
Furthermore,	O
a	O
single	B-Genetic
rigidifying	I-Genetic
mutation	I-Genetic
within	O
this	O
loop	O
can	O
significantly	O
improve	O
the	O
enzyme	B-Molecular
specific	I-Molecular
activity	I-Molecular
,	O
as	O
well	O
as	O
the	O
stability	O
to	O
thermal	O
denaturation	B-Molecular
and	O
aggregation	O
,	O
to	O
give	O
an	O
increased	O
temperature	O
optimum	O
for	O
activity	B-Molecular
.	O
	
==DOCSTART==	
Expression	B-Genetic
and	O
Purification	B-Laboratory
of	O
E2	O
Glycoprotein	O
from	O
Insect	B-Eukaryote
Cells	B-Cell
(	O
Sf9	B-Cell
)	O
for	O
Use	O
in	O
Serology	B-Laboratory
Chikungunya	B-Virus
virus	I-Virus
(	O
CHIKV	B-Virus
)	O
is	O
a	O
mosquito	B-Eukaryote
-	O
borne	B-Finding
arbovirus	B-Virus
which	O
poses	O
a	O
major	O
threat	O
to	O
global	O
public	O
health	O
.	O
Definitive	O
CHIKV	B-Virus
diagnosis	B-Finding
is	O
crucial,	O
especially	O
in	O
distinguishing	O
the	O
disease	B-Disease
from	O
dengue	B-Virus
virus	I-Virus
,	O
which	O
co-circulates	O
in	O
endemic	O
areas	O
and	O
shares	O
the	O
same	O
mosquito	B-Eukaryote
vectors	I-Eukaryote
.	O
Laboratory	B-Diagnostic
diagnosis	I-Diagnostic
is	O
mainly	O
based	O
on	O
serological	O
or	O
molecular	O
approaches.	O
The	O
E2	O
glycoprotein	O
is	O
a	O
good	O
candidate	O
for	O
serological	B-Laboratory
diagnosis	I-Laboratory
since	O
it	O
is	O
the	O
immunodominant	B-Immunologic
antigen	I-Immunologic
during	O
the	O
course	O
of	O
infection	B-Pathologic
,	O
and	O
reacts	O
with	O
seropositive	O
CHIKV	B-Virus
sera	B-Body
.	O
In	O
this	O
chapter	O
,	O
we	O
describe	O
the	O
generation	O
of	O
stable	O
clone	B-Cell
Sf9	B-Cell
(	O
Spodoptera	B-Eukaryote
frugiperda	I-Eukaryote
)	O
cells	B-Cell
expressing	B-Genetic
secreted	B-Cell
,	O
soluble	B-Cell
,	O
and	O
native	O
recombinant	O
CHIKV	B-Virus
E2	O
glycoprotein.	O
We	O
use	O
direct	O
plasmid	O
expression	B-Therapeutic
in	O
insect	B-Eukaryote
cells	B-Cell
,	O
rather	O
than	O
the	O
traditional	O
technique	O
of	O
generating	O
recombinant	B-Virus
baculovirus	I-Virus
.	O
This	O
recombinant	B-Amino
protein	I-Amino
is	O
useful	O
for	O
serological	B-Laboratory
diagnosis	I-Laboratory
of	O
CHIKV	B-Virus
infection	B-Pathologic
.	O
	
==DOCSTART==	
Acute	O
risk	B-Finding
factors	I-Finding
for	O
suicide	B-Finding
attempts	I-Finding
and	O
death	B-Finding
:	O
prospective	O
findings	O
from	O
the	O
STEP	O
-	O
BD	B-Mental
study	O
Suicide	B-Finding
is	O
unfortunately	O
common	O
in	O
psychiatric	O
practice	B-Mental
,	O
but	O
difficult	O
to	O
predict	O
.	O
The	O
present	O
study	O
sought	O
to	O
assess	O
which	O
clinical	O
symptoms	B-Sign
increase	O
in	O
the	O
months	O
before	O
suicidal	B-Finding
behavior	I-Finding
in	O
a	O
sample	O
of	O
psychiatric	O
outpatients	O
with	O
bipolar	B-Mental
disorder	I-Mental
.	O
Data	O
from	O
the	O
Systematic	O
Treatment	O
Enhancement	O
Program	O
for	O
Bipolar	B-Mental
Disorder	I-Mental
(	O
STEP	O
-	O
BD	B-Mental
)	O
trial	O
were	O
used.	O
A	O
total	O
of	O
103	O
participants	O
who	O
attempted	B-Finding
suicide	I-Finding
or	O
died	B-Finding
by	O
suicide	B-Finding
during	O
the	O
trial	O
were	O
included;	O
a	O
15%	O
random	O
sample	O
of	O
the	O
remaining	O
participants	O
(n	O
=	O
427)	O
was	O
used	O
as	O
a	O
comparison	O
sample	O
.	O
Linear	O
mixed	O
models	O
in	O
the	O
six	O
months	O
before	O
suicidal	B-Finding
behavior	I-Finding
were	O
conducted	O
for	O
each	O
of	O
five	O
proposed	O
acute	O
risk	B-Finding
factors	I-Finding
for	O
suicidal	B-Finding
behavior	I-Finding
.	O
Participants	O
were	O
assessed	O
using	O
the	O
Clinical	O
Monitoring	O
Form	O
(	O
CMF	O
)	O
at	O
each	O
visit	O
for	O
the	O
following	O
potential	O
acute	O
risk	B-Finding
factors	I-Finding
for	O
suicidal	B-Finding
behavior	I-Finding
:	O
suicidal	B-Finding
ideation	I-Finding
,	O
loss	B-Finding
of	I-Finding
interest	I-Finding
,	O
anxiety	B-Finding
,	O
psychomotor	B-Finding
agitation	I-Finding
,	O
and	O
high-risk	O
behavior	O
.	O
Each	O
of	O
the	O
five	O
symptoms	B-Sign
was	O
elevated	O
overall	O
in	O
individuals	O
who	O
engaged	O
in	O
suicidal	B-Finding
behavior	I-Finding
(p	O
<	O
0.05).	O
The	O
severity	O
of	O
both	O
suicidal	B-Finding
ideation	I-Finding
and	O
loss	B-Finding
of	I-Finding
interest	I-Finding
significantly	O
increased	O
in	O
the	O
months	O
before	O
suicidal	B-Finding
behavior	I-Finding
(p	O
<	O
0.001).	O
Anxiety	B-Finding
demonstrated	O
comparable	O
effect	O
sizes	O
across	O
multiple	O
models	O
.	O
Psychomotor	B-Finding
agitation	I-Finding
and	O
high-risk	O
behavior	O
were	O
not	O
significantly	O
elevated	O
before	O
suicidal	B-Finding
behavior	I-Finding
.	O
Suicidal	B-Finding
ideation	I-Finding
,	O
loss	B-Finding
of	I-Finding
interest	I-Finding
and,	O
to	O
a	O
lesser	O
extent	O
,	O
anxiety	B-Finding
may	O
represent	O
	
==DOCSTART==	
acute	O
suicide	B-Finding
risk	B-Finding
factors	I-Finding
up	O
to	O
four	O
months	O
before	O
suicidal	B-Finding
behavior	I-Finding
in	O
outpatients	O
with	O
bipolar	B-Mental
disorder	I-Mental
.	O
Further	O
investigation	O
of	O
these	O
potential	O
acute	O
risk	B-Finding
factors	I-Finding
in	O
prospective	O
analyses	O
is	O
warranted.	O
	
==DOCSTART==	
Measurement	O
of	O
Outcomes	O
of	O
Upper	B-Finding
Limb	I-Finding
Reconstructive	I-Finding
Surgery	I-Finding
for	O
Tetraplegia	B-Disease
Reconstructive	B-Finding
arm/hand	I-Finding
surgery	I-Finding
for	O
tetraplegia	B-Disease
is	O
performed	O
to	O
improve	B-Finding
arm/hand	B-Organism
function	I-Organism
and	O
therefore	O
personal	B-Finding
well-being	I-Finding
for	O
individuals	O
who	O
accept	O
such	O
elective	B-Therapeutic
surgeries	I-Therapeutic
.	O
However,	O
changes	O
at	O
an	O
impairment	O
level	O
do	O
not	O
always	O
translate	O
into	O
functional	O
or	O
quality	O
of	O
life	O
changes	O
.	O
Therefore,	O
multiple	O
outcome	O
tools	O
should	O
be	O
used	O
that	O
incorporate	O
sufficient	B-Finding
responsiveness	I-Finding
to	O
detect	B-Finding
changes	O
in	O
arm/hand	B-Organism
function	I-Organism
,	O
activity	O
and	O
participation	O
,	O
and	O
quality	O
of	O
life	O
of	O
the	O
individuals	O
involved.	O
This	O
narrative	O
review	O
aims	O
to	O
assist	O
clinicians	O
to	O
choose	O
the	O
most	O
appropriate	O
tools	O
to	O
assess	O
the	O
need	O
for	O
reconstructive	B-Finding
surgery	I-Finding
and	O
to	O
evaluate	O
its	O
outcomes	O
.	O
Our	O
specific	O
objectives	O
are	O
(1)	O
to	O
describe	O
aspects	O
to	O
consider	O
when	O
choosing	O
a	O
measure	O
and	O
(2)	O
to	O
describe	O
the	O
measures	O
advised	O
by	O
an	O
international	O
therapist	O
consensus	O
group	O
established	O
in	O
2007.	O
All	O
advised	O
measures	O
are	O
appraised	O
in	O
terms	O
of	O
the	O
underlying	O
construct	O
,	O
administration	B-Therapeutic
,	O
and	O
clinical	O
relevance	O
to	O
arm/hand	B-Therapeutic
reconstructions	I-Therapeutic
.	O
Essentially	O
there	O
are	O
currently	O
no	O
criterion	O
standard	O
measures	O
to	O
evaluate	O
the	O
consequences	O
of	O
reconstructive	B-Finding
arm/hand	I-Finding
surgery	I-Finding
.	O
However,	O
with	O
judicious	O
use	O
of	O
available	O
measures	O
it	O
is	O
possible	O
to	O
ensure	O
the	O
questions	B-Finding
asked	I-Finding
or	O
tasks	O
completed	O
are	O
relevant	O
to	O
the	O
surgical	B-Therapeutic
reconstruction	I-Therapeutic
(s)	O
undertaken.	O
Further	O
work	O
in	O
this	O
field	O
is	O
required	O
.	O
This	O
would	O
be	O
best	O
met	O
by	O
immediate	O
collaboration	O
between	O
2	O
outcome's	O
tool	O
developers	O
and	O
by	O
analysis	O
of	O
pre	O
-	O
and	O
postoperative	O
data	O
already	O
held	O
in	O
various	O
international	O
sites,	O
which	O
would	O
allow	O
further	O
evaluation	O
of	O
the	O
measures	O
already	O
in	O
use	O
,	O
or	O
	
==DOCSTART==	
components	O
thereof.	O
	
==DOCSTART==	
Basal	B-Organism
and	O
maximal	O
metabolic	B-Physiologic
rates	I-Physiologic
differ	O
in	O
their	O
response	O
to	O
rapid	O
temperature	O
change	O
among	O
avian	O
species	O
In	O
birds	O
,	O
acclimation	B-Organism
and	O
acclimatization	B-Organism
to	O
temperature	O
are	O
associated	O
with	O
changes	O
in	O
basal	B-Organism
(	O
BMR	B-Organism
),	O
summit	B-Physiologic
(	O
Msum	B-Physiologic
)	O
and	O
maximal	O
(	O
MMR	B-Physiologic
)	O
metabolic	B-Physiologic
rates	I-Physiologic
but	O
little	O
is	O
known	O
about	O
the	O
rate	B-Physiologic
at	O
which	O
species	O
adjust	O
their	O
phenotype	O
to	O
short-term	O
temperature	O
variations	O
.	O
Our	O
aims	O
were	O
(1)	O
to	O
determine	O
the	O
pattern	O
of	O
metabolic	O
adjustments	O
following	O
a	O
rapid	O
temperature	O
change	O
,	O
(2)	O
to	O
determine	O
whether	O
performance	O
varies	O
at	O
similar	O
rates	B-Physiologic
during	O
exposure	O
to	O
warm	O
or	O
cold	O
environments	O
,	O
and	O
(3)	O
to	O
determine	O
if	O
BMR	B-Organism
,	O
Msum	B-Physiologic
and	O
MMR	B-Physiologic
change	O
at	O
comparable	O
rates	B-Physiologic
during	O
thermal	O
acclimation	B-Organism
.	O
We	O
measured	O
these	O
parameters	O
in	O
white-throated	O
sparrows	O
(	O
Zonotrichia	O
albicollis	O
),	O
black-capped	O
chickadees	O
(	O
Poecile	O
atricapillus	O
),	O
and	O
snow	O
buntings	O
(	O
Plectrophenax	O
nivalis	O
)	O
after	O
acclimation	B-Organism
to	O
10	O
°C	O
(	O
day	O
0)	O
and	O
on	O
the	O
4th	O
and	O
8th	O
days	O
of	O
acclimation	B-Organism
to	O
either	O
-5	O
or	O
28	O
°C.	O
Birds	O
changed	O
their	O
metabolic	O
phenotype	O
within	O
8	O
days	O
with	O
patterns	O
differing	O
among	O
species	O
.	O
Sparrows	O
expressed	O
the	O
expected	O
metabolic	O
increases	O
in	O
the	O
cold	O
and	O
decreases	O
at	O
thermoneutrality	O
while	O
performance	O
in	O
chickadees	O
and	O
buntings	O
was	O
not	O
influenced	O
by	O
temperature	O
but	O
changed	O
over	O
time	O
with	O
inverse	O
patterns	O
.	O
Our	O
results	B-Finding
suggest	O
that	O
BMR	B-Organism
varies	O
at	O
comparable	O
rates	B-Physiologic
in	O
warm	O
and	O
cold	O
environments	O
but	O
changes	O
faster	O
than	O
Msum	B-Physiologic
and	O
MMR	B-Physiologic
,	O
likely	O
due	O
to	O
limitations	O
in	O
the	O
rate	B-Physiologic
of	O
change	O
in	O
organ	O
size	O
and	O
function	O
.	O
They	O
also	O
suggest	O
that	O
maximal	O
metabolic	O
	
==DOCSTART==	
capacity	O
is	O
lost	O
faster	O
in	O
a	O
warm	O
environment	O
than	O
it	O
is	O
gained	O
in	O
a	O
cold	O
environment	O
.	O
With	O
the	O
expected	O
increase	O
in	O
temperature	O
stochasticity	O
at	O
northern	O
latitudes	O
,	O
a	O
loss	O
of	O
thermogenic	O
capacity	O
during	O
warm	O
winter	O
days	O
could,	O
therefore,	O
be	O
detrimental	O
if	O
birds	O
are	O
slow	O
to	O
readjust	O
their	O
phenotype	O
with	O
the	O
return	O
of	O
cold	O
days	O
.	O
	
==DOCSTART==	
Factors	O
preventing	O
kneeling	B-Physiologic
in	O
a	O
group	O
of	O
pre-educated	O
patients	O
post	O
total	B-Therapeutic
knee	I-Therapeutic
arthroplasty	I-Therapeutic
Difficulties	B-Finding
in	I-Finding
kneeling	I-Finding
,	O
one	O
of	O
the	O
poorest	B-Finding
scoring	I-Finding
functional	I-Finding
outcomes	I-Finding
post	O
total	B-Therapeutic
knee	I-Therapeutic
arthroplasty	I-Therapeutic
(	O
TKA	B-Therapeutic
),have	O
been	O
attributed	O
to	O
a	O
lack	O
of	O
patient	O
education	O
.	O
This	O
is	O
the	O
first	O
study	O
to	O
investigate	O
specific	O
factors	O
affecting	O
a	O
patient's	O
perceived	B-Mental
ability	O
to	O
kneel	O
post	O
TKA	B-Therapeutic
,	O
following	O
exposure	O
to	O
a	O
preoperative	O
kneeling	B-Physiologic
education	O
session	O
.	O
A	O
cross-sectional	O
study	O
was	O
conducted	O
following	O
TKA	B-Therapeutic
with	O
patients	O
who	O
had	O
been	O
educated	O
about	O
kneeling	B-Physiologic
prior	O
to	O
the	O
operation	B-Therapeutic
.	O
Patients	O
completed	O
kneeling	B-Physiologic
questionnaires	O
at	O
6	O
(n	O
=	O
115)	O
and	O
12	O
(n	O
=	O
82)	O
months	O
post	O
TKA	B-Therapeutic
.	O
In	O
addition	O
to	O
the	O
12-month	O
kneeling	B-Physiologic
questionnaire	O
,	O
patients	O
also	O
completed	O
the	O
Oxford	O
knee	O
score	O
(	O
OKS	O
)	O
survey.	O
Seventy-two	O
percent	O
of	O
patients	O
perceived	B-Mental
they	O
could	O
kneel	B-Physiologic
at	O
12	O
months	O
post	O
TKA	B-Therapeutic
.	O
Overall,	O
pain	B-Sign
and	O
discomfort	B-Sign
were	O
the	O
most	O
common	O
factors	O
deterring	O
patients	O
from	O
kneeling	B-Physiologic
.	O
Perceived	B-Mental
kneeling	B-Physiologic
ability	O
was	O
the	O
poorest	O
scored	O
outcome	O
on	O
the	O
OKS	O
with	O
patients	O
reporting	O
mild	O
to	O
moderate	O
difficulty	B-Finding
with	O
this	O
task.	O
Kneeling	B-Physiologic
scores	O
were	O
strongly	O
correlated	O
with	O
overall	O
knee	B-Finding
function	I-Finding
scores	I-Finding
(R	O
=	O
0.70),	O
strongly	O
correlated	O
with	O
pain	B-Finding
scores	I-Finding
(R	O
=	O
0.45)	O
and	O
weakly	O
correlated	O
with	O
knee	B-Finding
stability	I-Finding
scores	I-Finding
(R	O
=	O
0.29).	O
When	O
asked	O
about	O
other	O
factors	O
preventing	O
kneeling	B-Physiologic
other	O
than	O
pain	B-Sign
or	O
discomfor	B-Sign
t,	O
75	O
%	O
had	O
reasons	O
unrelated	B-Finding
to	O
the	O
knee	B-Body
or	O
TKA	B-Therapeutic
.	O
The	O
most	O
common	O
reason	O
was	O
'problems	O
with	O
the	O
other	O
knee	B-Body
'	O
(n	O
=	O
19).	O
Patients	O
in	O
this	O
study	O
were	O
provided	O
with	O
	
==DOCSTART==	
education	O
regarding	O
their	O
kneeling	B-Physiologic
ability	O
post	O
TKA	B-Therapeutic
,	O
yet	O
still	O
experienced	O
limitations	O
in	O
perceived	B-Mental
kneeling	B-Physiologic
ability	O
post	O
operatively.	O
Contrary	O
to	O
previous	O
research,	O
our	O
study	O
suggests	O
that	O
factors	O
other	O
than	O
patient	O
education	O
affect	O
a	O
patient's	O
perceived	B-Mental
kneeling	B-Physiologic
ability	O
post	O
TKA	B-Therapeutic
.	O
	
==DOCSTART==	
Improved	B-Finding
diagnostic	O
yield	O
of	O
neuromuscular	B-Disease
disorders	I-Disease
applying	O
clinical	O
exome	B-Molecular
sequencing	I-Molecular
in	O
patients	O
arising	O
from	O
a	O
consanguineous	O
population	O
Neuromuscular	B-Disease
diseases	I-Disease
(	O
NMDs	B-Disease
)	O
include	O
a	O
broad	O
range	O
of	O
disorders	B-Disease
affecting	O
muscles	B-Tissue
,	O
nerves	B-Tissue
and	O
neuromuscular	B-Cell
junctions	I-Cell
.	O
Their	O
overlapping	O
phenotypes	O
and	O
heterogeneous	O
genetic	O
nature	O
have	O
created	O
challenges	O
in	O
diagnosis	B-Finding
which	O
calls	O
for	O
the	O
implementation	O
of	O
massive	B-Molecular
parallel	I-Molecular
sequencing	I-Molecular
as	O
a	O
candidate	O
strategy	O
to	O
increase	O
the	O
diagnostic	O
yield	O
.	O
In	O
this	O
study	O
,	O
total	O
of	O
45	O
patients	O
,	O
mostly	O
offspring	O
of	O
consanguineous	O
marriages	O
were	O
examined	O
using	O
whole	B-Molecular
exome	I-Molecular
sequencing	I-Molecular
.	O
Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	B-Finding
rare	O
variants	O
in	O
known	O
NMD	B-Disease
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(73.3%)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	B-Finding
variants	O
were	O
detected	B-Finding
.	O
Today,	O
the	O
advantage	O
of	O
whole	B-Molecular
exome	I-Molecular
sequencing	I-Molecular
in	O
clinical	B-Diagnostic
diagnostic	I-Diagnostic
strategies	O
of	O
heterogeneous	B-Finding
disorders	I-Finding
is	O
clear.	O
In	O
this	O
cohort	O
,	O
a	O
diagnostic	O
yield	O
of	O
73.3%	O
was	O
achieved	O
which	O
is	O
quite	O
high	O
compared	O
to	O
the	O
overall	O
reported	O
diagnostic	O
yield	O
of	O
25%	O
to	O
50%.	O
This	O
could	O
be	O
explained	O
by	O
the	O
consanguineous	O
background	O
of	O
these	O
patients	O
and	O
is	O
another	O
strong	O
advantage	O
of	O
offering	O
clinical	O
exome	B-Molecular
sequencing	I-Molecular
in	O
diagnostic	O
laboratories,	O
especially	O
in	O
populations	O
with	O
high	O
rate	O
of	O
consanguinity	B-Finding
.	O
	
==DOCSTART==	
Safety	O
of	O
transradial	B-Diagnostic
diagnostic	I-Diagnostic
cardiac	I-Diagnostic
catheterization	I-Diagnostic
in	O
patients	O
under	O
oral	O
anticoagulant	B-Therapeutic
therapy	I-Therapeutic
Cardiac	O
catheterization	O
in	O
anticoagulated	O
patients	O
is	O
usually	O
performed	O
after	O
the	O
anticoagulation	B-Therapeutic
has	O
been	O
withdrawn	B-Therapeutic
,	O
at	O
least	O
in	O
the	O
previous	O
48h,	O
and	O
sometimes	O
bridging	B-Therapeutic
therapy	I-Therapeutic
with	I-Therapeutic
heparin	I-Therapeutic
is	O
used.	O
A	O
prospective	O
observational	O
study	O
including	O
489	O
patients	O
undergoing	O
transradial	O
catheterization	O
was	O
conducted.	O
A	O
total	O
of	O
140	O
patients	O
were	O
under	O
acenocoumarol	O
(	O
group	O
A	O
)	O
and	O
they	O
were	O
compared	O
with	O
the	O
remainder	O
(	O
group	O
B	O
)	O
for	O
complications	B-Pathologic
after	O
the	O
procedure	O
(	O
bleeding	B-Pathologic
and	O
vascular	B-Pathologic
access	I-Pathologic
complications	I-Pathologic
).	O
Patients	O
in	O
group	O
A	O
were	O
older	O
(74±12	O
years	O
vs.	O
68±17	O
years,	O
p<0.01)	O
and	O
the	O
main	O
indication	O
for	O
anticoagulation	B-Therapeutic
was	O
atrial	B-Disease
fibrillation	I-Disease
(58.6%).	O
No	B-Finding
complications	B-Pathologic
occurred	O
during	O
the	O
procedures	O
.	O
There	O
were	O
no	B-Finding
acute	B-Pathologic
bleedings	I-Pathologic
just	O
after	O
the	O
bandage	B-Medical
removal	O
.	O
During	O
the	O
first	O
24h,	O
only	O
3	O
(2.1%)	O
radial	B-Pathologic
occlusions	I-Pathologic
in	O
group	O
A	O
and	O
2	O
(0.6%)	O
in	O
group	O
B	O
(p=0.14)	O
were	O
recorded	O
.	O
Hematomas	B-Pathologic
between	O
5	O
and	O
10cm	O
appeared	O
in	O
5%	O
of	O
the	O
group	O
A	O
vs.	O
4.6%	O
in	O
group	O
B	O
.	O
During	O
the	O
1-month	O
follow-up	O
period	O
,	O
one	O
more	O
radial	B-Pathologic
occlusion	I-Pathologic
in	O
each	O
group	O
was	O
recorded	O
and	O
there	O
were	O
4	O
(1.1%)	O
additional	O
mild	O
hematomas	B-Pathologic
in	O
group	O
B	O
and	O
none	O
in	O
group	O
A	O
(p=0.48).	O
Performing	O
a	O
transradial	B-Diagnostic
diagnostic	I-Diagnostic
cardiac	I-Diagnostic
catheterization	I-Diagnostic
without	O
removal	O
of	O
the	O
oral	O
chronic	O
anticoagulation	O
appears	O
safe	B-Finding
in	O
patients	O
under	O
acenocumarol	O
therapy	B-Therapeutic
.	O
	
==DOCSTART==	
Does	O
infrared	B-Medical
visualization	O
improve	O
selection	O
of	O
venipuncture	B-Diagnostic
sites	O
for	O
indwelling	O
needle	B-Medical
at	O
the	O
forearm	B-Body
in	O
second-year	O
nursing	O
students	O
?	O
To	O
evaluate	O
the	O
effectiveness	O
of	O
a	O
vein	B-Medical
visualization	I-Medical
display	I-Medical
system	I-Medical
using	O
near-infrared	O
light	O
("	O
Vein	B-Medical
Display	I-Medical
")	O
for	O
the	O
safe	O
and	O
proper	O
selection	O
of	O
venipuncture	B-Diagnostic
sites	O
for	O
indwelling	O
needle	B-Medical
placement	O
in	O
the	O
forearm	B-Body
.	O
Ten	O
second	O
year	O
nursing	O
students	O
were	O
recruited	O
to	O
apply	O
an	O
indwelling	O
needle	B-Medical
line	O
with	O
and	O
without	O
Vein	B-Body
Display	O
.	O
Another	O
ten	O
participants	O
were	O
recruited	O
from	O
various	O
faculty	O
to	O
serve	O
as	O
patients	O
.	O
The	O
quality	O
of	O
the	O
venipuncture	B-Diagnostic
procedure	I-Diagnostic
at	O
various	O
selected	O
sites	O
was	O
evaluated	O
according	O
to	O
a	O
scale	O
developed	O
by	O
the	O
authors	O
.	O
Time	O
,	O
scores	O
and	O
patterns	O
of	O
puncture	B-Diagnostic
-	O
site	O
selection	O
were	O
compared	O
with	O
respect	O
to	O
three	O
different	O
methods:	O
[1]	O
attempt	O
1	O
(	O
tourniquet	B-Medical
only),	O
[2]	O
attempt	O
2	O
(	O
Vein	B-Medical
Display	I-Medical
only)	O
and	O
[3]	O
attempt	O
3	O
(both).	O
To	O
validate	O
the	O
effectiveness	O
of	O
Vein	B-Body
Display	O
,	O
52	O
trials	O
were	O
conducted	O
in	O
total.	O
We	O
found	O
that	O
venipuncture	B-Diagnostic
site	O
selection	O
time	O
was	O
significantly	O
improved	O
with	O
the	O
Vein	B-Medical
Display	I-Medical
,	O
particularly	O
in	O
the	O
case	O
of	O
difficult	O
to	O
administer	O
venipuncture	B-Diagnostic
sites	O
.	O
Overall,	O
we	O
found	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
venipuncture	B-Diagnostic
quality	O
,	O
as	O
determined	O
by	O
our	O
scale	O
.	O
These	O
results	O
suggest	O
that	O
equipment	O
such	O
as	O
the	O
Vein	B-Medical
Display	I-Medical
can	O
contribute	O
immensely	O
to	O
the	O
improvement	O
of	O
practical	O
skills	O
,	O
such	O
as	O
venipuncture	B-Diagnostic
,	O
especially	O
in	O
the	O
context	O
of	O
elderly	O
patients	O
.	O
	
==DOCSTART==	
Elective	B-Therapeutic
Nephron	B-Therapeutic
Sparing	I-Therapeutic
Surgery	I-Therapeutic
Decreases	O
Other	B-Finding
Cause	I-Finding
Mortality	I-Finding
Relative	O
to	O
Radical	B-Therapeutic
Nephrectomy	I-Therapeutic
Only	O
in	O
Specific	O
Subgroups	O
of	O
Patients	O
with	O
Renal	B-Neoplastic
Cell	I-Neoplastic
Carcinoma	I-Neoplastic
There	O
is	O
no	O
consensus	O
regarding	O
a	O
protective	B-Finding
effect	I-Finding
on	O
mortality	O
due	O
to	O
a	O
cause	O
other	O
than	O
cancer	B-Neoplastic
in	O
patients	O
treated	B-Therapeutic
with	I-Therapeutic
elective	B-Therapeutic
nephron	B-Therapeutic
sparing	I-Therapeutic
surgery	I-Therapeutic
relative	O
to	O
their	O
radical	B-Therapeutic
nephrectomy	I-Therapeutic
counterparts.	O
We	O
test	O
whether	O
the	O
protective	B-Finding
effect	I-Finding
of	O
nephron	B-Therapeutic
sparing	I-Therapeutic
surgery	I-Therapeutic
relative	O
to	O
radical	B-Therapeutic
nephrectomy	I-Therapeutic
is	O
universal	O
or	O
present	O
in	O
specific	O
subgroups	O
of	O
patients	O
.	O
A	O
collaborative	O
database	O
of	O
5	O
institutions	O
was	O
queried	O
to	O
evaluate	O
1,783	O
patients	O
without	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
diagnosed	B-Finding
with	O
a	O
clinical	O
T1	B-Neoplastic
renal	I-Neoplastic
mass	I-Neoplastic
that	O
was	O
treated	B-Therapeutic
with	I-Therapeutic
nephron	B-Therapeutic
sparing	I-Therapeutic
surgery	I-Therapeutic
or	O
radical	B-Therapeutic
nephrectomy	I-Therapeutic
.	O
Multivariable	O
Cox	O
regression	O
analysis	O
was	O
done	O
to	O
assess	O
the	O
impact	O
of	O
surgery	B-Therapeutic
type	O
(	O
nephron	B-Therapeutic
sparing	I-Therapeutic
surgery	I-Therapeutic
vs	O
radical	B-Therapeutic
nephrectomy	I-Therapeutic
)	O
on	O
other	B-Finding
cause	I-Finding
mortality	I-Finding
after	O
adjustment	O
for	O
patient	O
and	O
cancer	B-Neoplastic
characteristics	O
.	O
Interaction	O
terms	O
were	O
used	O
to	O
test	O
the	O
hypothesis	O
that	O
the	O
impact	O
of	O
surgery	B-Therapeutic
type	O
varies	O
according	O
to	O
specific	O
subcohorts	O
of	O
patients	O
.	O
Ten-year	O
other	B-Finding
cause	I-Finding
mortality	I-Finding
-free	O
survival	O
rates	O
were	O
90%	O
and	O
88%	O
after	O
nephron	B-Therapeutic
sparing	I-Therapeutic
surgery	I-Therapeutic
and	O
radical	B-Therapeutic
nephrectomy	I-Therapeutic
,	O
respectively.	O
In	O
the	O
overall	O
population	O
radical	B-Therapeutic
nephrectomy	I-Therapeutic
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
other	B-Finding
cause	I-Finding
mortality	I-Finding
on	O
multivariable	O
analysis	O
compared	O
to	O
nephron	B-Therapeutic
sparing	I-Therapeutic
surgery	I-Therapeutic
(	O
HR	O
0.91,	O
95%	O
CI	O
0.6-1.38,	O
p	O
=	O
0.6).	O
However,	O
radical	B-Therapeutic
nephrectomy	I-Therapeutic
increased	O
the	O
risk	O
of	O
other	B-Finding
cause	I-Finding
mortality	I-Finding
according	O
to	O
the	O
increasing	O
baseline	O
Charlson	O
comorbidity	O
index	O
(	O
interaction	O
test	O
p	O
=	O
0.0008).	O
For	O
example,	O
in	O
a	O
patient	O
with	O
	
==DOCSTART==	
a	O
Charlson	O
comorbidity	O
index	O
of	O
4	O
the	O
probability	O
of	O
10-year	O
other	B-Finding
cause	I-Finding
mortality	I-Finding
-free	O
survival	O
was	O
86%	O
after	O
nephron	B-Therapeutic
sparing	I-Therapeutic
surgery	I-Therapeutic
and	O
60%	O
after	O
radical	B-Therapeutic
nephrectomy	I-Therapeutic
.	O
Elective	B-Therapeutic
nephron	B-Therapeutic
sparing	I-Therapeutic
surgery	I-Therapeutic
does	O
not	O
improve	B-Finding
other	O
cause	O
survival	O
relative	O
to	O
radical	B-Therapeutic
nephrectomy	I-Therapeutic
consistently	O
in	O
all	O
patients	O
with	O
kidney	B-Neoplastic
cancer	I-Neoplastic
.	O
Patients	O
who	O
are	O
more	O
ill	B-Sign
with	O
relevant	O
comorbidities	O
are	O
those	O
who	O
benefit	O
the	O
most	O
from	O
nephron	B-Therapeutic
sparing	I-Therapeutic
surgery	I-Therapeutic
in	O
terms	O
of	O
other	B-Finding
cause	I-Finding
mortality	I-Finding
.	O
	
==DOCSTART==	
A	O
prime	B-Mental
a	O
day	O
keeps	O
calories	O
away:	O
The	O
effects	O
of	O
supraliminal	B-Mental
priming	I-Mental
on	O
food	O
consumption	O
and	O
the	O
moderating	O
role	O
of	O
gender	O
and	O
eating	O
restraint	O
The	O
link	O
between	O
intentions	B-Mental
and	O
action	O
in	O
weight	B-Therapeutic
control	I-Therapeutic
is	O
weaker	O
than	O
previously	O
thought,	O
so	O
recent	O
research	O
has	O
called	O
for	O
further	O
investigation	O
of	O
ways	O
to	O
improve	O
weight	B-Therapeutic
control	I-Therapeutic
that	O
bypass	O
conscious	B-Mental
intentions	B-Mental
.	O
Priming	B-Mental
has	O
been	O
shown	O
to	O
have	O
effects	O
on	O
individual	O
behavior	O
in	O
a	O
variety	O
of	O
contexts	O
by	O
influencing	O
subconscious	B-Mental
cognition	B-Mental
.	O
This	O
paper	O
investigates	O
the	O
effects	O
of	O
semantic	O
priming	O
using	O
healthy	O
body	B-Mental

